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ABSTRACT
The emergence of antibiotic-resistant bacteria necessitates the discovery of new
classes of antibiotics acting through novel mechanisms. The bacterial sliding clamp,
also known as the DNA polymerase III β subunit, engages in multiple protein-protein
interactions by recognizing conserved penta- or hexapeptide motifs in various binding
partners during DNA replication and repair. The central role of the sliding clamp in
DNA replication and repair make it an attractive antibiotic target.

Protein-protein interactions based on linear motif (LM) recognition play roles in
many cell regulatory processes. The E. coli sliding clamp uses a common surface pocket
composed of two sub-sites (I and II) to interact with LMs in multiple binding partners.
A structural and thermodynamic dissection of sliding clamp-LM recognition has been
performed, providing support for a sequential binding model. According to the model, a
hydrophobic C-terminal LM dipeptide sub-motif acts as an anchor to establish initial
contacts within subsite I and this is followed by formation of a stabilizing hydrogenbonding network between the flanking LM residues and subsite II. Differential
solvation/desolvation effects during positioning of the sub-motifs are proposed to act as
drivers of sequential binding. This model provides general insights into linear motif
recognition and should guide the design of small-molecule inhibitors of the E. coli
sliding clamp.

Following the study of the LM recognition, fragment-based screening against the E.
coli sliding clamp using X-ray crystallography, was carried out. Screening 352 fragment
compounds produced hits bound at one of the two LM-binding subsites (subsites I).
These fragment compounds were estimated to have millimolar binding affinity to the E.
coli sliding clamp. A number of small-molecule inhibitors were designed based on the
ix

fragment hits, aided by molecular docking, and were found to bind to subsite I and
inhibit LM-binding by the E. coli sliding clamp. They showed increased affinity at the
micromolar level. From these, compounds with a tetrahydrocarbazole scaffold were
chosen for lead development. A lead compound with tetrahydrocarbazole scaffold was
designed to target both subsite I and subsite II. This work yielded a range of inhibitors
with low-micromolar affinity with the potential to be a new class of antibiotics.

This work reveals a sequential binding model of LM recognition by the E. coli
sliding clamp. Fragment-based inhibitor design was carried out with the aim to find
novel antibiotics with novel mechanism(s) of action. The inhibitor design improved the
affinity from millimolar to low-micromolar level, providing a tetrahydrocarbazole
scaffold with the potential for further optimization.
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Chapter 1
General Introduction
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1.1 Antibiotic design targeting the protein-protein interaction network mediated
by the bacterial sliding clamp
The emergence of antibiotic-resistant bacteria represents a great challenge to
medicinal chemistry2 and new classes of antibiotics with novel targets and modes of
action are desperately needed.3-5 Targeting the bacterial DNA replication machinery is a
validated strategy for producing clinically useful antibiotics, as evidenced by the highly
successful quinolones (DNA gyrase inhibitors).6
DNA replication in the three domains of life involve a ring-shaped clamp-like
protein that encircles DNA and confers processivity to DNA replication.7-9 This
mechanism was first discovered in Escherichia coli in which a homodimer, the βsubunit of DNA polymerase III holoenzyme, was identified as a sliding clamp (SC).10 In
DNA replication, the SC is loaded onto DNA by the clamp-loader complex (composed
of Pol III δ, γ/τ and δ’ subunits)11-13 and confers high processivity upon the Pol III α
subunit (the replicase) by acting as a mobile tether:14,15 The SCis loaded onto the primed
DNA by the clamp loader complex and is subsequently released. The α subunit binds to
the SC and catalyzes extension of the primer through incorporation of dNTPs using
ssDNA as a template.
The SC is involved in a variety of bacterial cellular events including DNA repair and
recombination via interactions with DnaA,16 DNA polymerase I,7 II,17 III,18 IV19 and
V20, DNA ligase7, MutS and MutL7,21, Hda,22 and UmuD23.
The extensive range of interactions of the SC opens the possibility of targeting it in
antibiotic development.24 It has been argued that the SC and another critical protein in
DNA replication, single-stranded DNA binding protein (SSB), represent the most
promising antibiotics targets in bacterial DNA replication.25 They both mediate complex
2

interaction networks but differ in the mechanism of molecular recognition: the SC
contains a specific peptide-binding pocket for partner binding, whereas SSB contains a
peptide motif recognized by its various binding partners. Inhibitor design efforts
targeting SSB interactions have commenced.26,27
The binding pocket of the bacterial SC is structurally conserved across bacterial
species. The eukaryote homolog of the sliding clamp, the proliferating cell nuclear
antigen (PCNA), shares no significant similarity at the amino acid sequence level, but
its topology is conserved (see below).7 The high level of structural conservation of the
SC across diverse organisms attests to the essential nature of the sliding clamp’s
functions.
Compounds that disrupt bacterial SC interactions could represent a new broadspectrum antibiotic. Development of resistance against such antibiotics is likely to
present a substantial challenge to bacteria: bypassing this essential protein is unlikely
and mutations in the binding site are expected to reduce the affinity of the target’s many
physiological binding partners, rendering mutants non-viable. The work described in the
thesis is aimed at developing small-molecule inhibitors that disrupt the protein-protein
interaction mediated by the E. coli sliding clamp.
1.2 The structure of bacterial sliding clamps
The first crystal structure of any SC was that from E. coli (β subunit of the DNA
polymerase III holoenzyme), solved by Kong and co-workers.28 The dimer displays C2
symmetry, forming a ring with an outer diameter of approximately 80 Å and an inner
diameter of approximately 35 Å, sufficient to accommodate dsDNA. Each monomer
contains 3 copies of the “DNA-clamp” domain (domains I, II and III) consisting of two
anti-parallel, 4-stranded β sheets and two α helices. Thus the clamp displays pseudo 6–
3

fold symmetry (Figure 1.1). This architecture allows the SC to encircle duplex DNA
and slide along it.28 This overall architecture is shared by PCNA although PCNA is a
homotrimer with each monomer containing two DNA-clamp domains.29
Burnouf and co-workers30 compared the sequences of bacterial SC homologues and
found the residues showing over 40% identity, 13 residues are more than 80%
conserved. Over the last two decades, structures of sliding clamps from various bacterial
species have been solved (Figure 1.1; Table 1.1) and indeed they show conserved
topology (Figure 1.1). A sequence alignment of the sliding clamps from nine bacterial
species (five Gram-negative and four Gram-positive) is shown in Figure 1.2. This
comparison suggests that the composition of the surface binding pocket is highly
conserved (See below).
The tertiary structures of sliding clamps differ slightly between Gram–positive and
Gram–negative species31. Available SC crystal structures can be categorized into two
classes: circular and elliptical (Figure 1.1a and b, respectively; Table 1). Escherichia
coli and Thermotoga maritima are Gram–negative species and their sliding clamps have
similar circular inner rings, as does Mycobacterium tuberculosis which may be
considered to be neither Gram-positive nor Gram-negative but is evolutionarily closer to
the latter.32 Eubacterium rectal, Streptococcus pyogenes and Streptococcus pneumoniae
are Gram–positive and their sliding clamps both adopt elliptical shapes due to the αhelices near the dimer interfaces being pulled away from the centre, while those distant
to the dimer interface are pushed inward (Figure 1.1).
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Table 1.1 Crystal structures of bacterial DNA Pol III beta subunit (the sliding clamp).
Unit cell
PDB
code

Species

Space
Group

a, b, c (Å)/α, β, γ (°)

Mutation

References

2POL

Escherichia coli

P21

80.61, 68.35, 82.35/90, 114.26, 90

N/A

28

2XUR

Escherichia coli

P21

79.98, 66.49, 81.70/90, 113.75, 90

G157C

33

3PWE

Escherichia coli

P21

79.80, 67.36, 80.74/90, 114.16, 90

3F1V

Escherichia coli

P1

40.84, 64.47, 72.11/73.83, 82.72, 83.76

1MMI

Escherichia coli

P21

80.01, 66.60, 80.78/90, 114.02, 90

N/A

36

3P16

Mycobacterium tuberculosis

P21

88.05, 132.97, 113.78/90, 109.05, 90

N/A

37

3T0P

Eubacterium rectale

C2

127.76, 95.56, 84.01/90, 115.94, 90

N/A

1VPK

Thermotoga maritima

P42212

91.70, 91.70, 111.46/90, 90, 90

N/A

2AVT

Streptococcus pyogenes

P21

79.04, 74.67, 82.78/90, 118.57, 90

N/A

2AWA

Streptococcus pneumoniae

P21

94.06, 70.72, 135.44/90, 91.04, 90

N/A

2

R103C, I305C, C260S,
C333S
H148A, Q149A, D150A,
V151A, R152A

34

35

To be
published
To be
published
31

To be
published

a

b

c

Figure 1.1 Superimposed crystal structures of the SC of Gram-negative bacteria (Red: E. coli and Yellow: T. maritima and Green: M.
tuberculosis) (a) and Gram-positive bacteria (Blue: E. rectale, Cyan: S. pyogenes and Pink: S. pneumoniae) (b). The E. coli and S. pyogenes beta
clamps are superimposed in (c). Arrows indicate the location of the dimer interface.
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Figure 1.2. Sequence alignment of sliding clamps from nine bacterial species. Residues comprising the surface binding pocket of the SC are
highlighted in yellow. Numbering is based on the E. coli SC sequence.
4

1.3 The E. coli SC binding pocket and its interaction with peptidic ligands, binding
ssDNA and small-molecule inhibitors
1.3.1 The binding pocket of the E. coli SC and the peptidic ligands
Studies found consensus sequences QL[S/D]LF and QLxLxF/L,18,38 in the sliding
clamp's partner proteins. A number of crystal structures of the E. coli SC in complex
with partner proteins or peptides derived from these partner proteins were solved. These
peptide ligands uniformly bind to a common pocket on the surface of the SC (Figure
1.3). This binding pocket consists of two subsites (Figure 1.4-1.7): subsite I (formed by
residues S346, V360, V347, L177, P242, Y154, T172, L155, R152, G174 and M362)
and subsite II (formed by residues M362, P363, N320, H175 and Y323).13,39 Burnouf
and co-workers30 found that 7 of 13 residues that are located at the peptide-binding site
are more than 80% conserved. This suggests that the SC binding sites are conserved
across bacterial species (see also Figure 1.2). This hypothesis was supported by the
later findings that the Mycobacterium tuberculosis SC binds two peptides derived from
Pol III α subunit C-terminus of the same species37 and binding by the Streptococcus
pyogenes SC of a Pol III δ-derived peptide.31
The structure of the E. coli SC in complex with the 'little finger' domain of Y-family
DNA polymerase IV, which binds to the SC with a C-terminal hexapeptide motif
(QLVLGL) is shown in Figure 1.4.39 E. coli SC structures in complex with peptides
derived from the Pol IV C-terminus (RQLVLGL),30 Pol III-α C-terminus
(SEQVELEFD)40 and Pol II (GQLGLF)39 were solved and the consensus binding motifs
observed (Figure 1.5-1.7).
In all structures of SC/peptide complexes, a glutamine residue of the peptide is
restrained by hydrogen bonds with a bridging water molecule and the backbone
5

carbonyl group of M362 of subsite II. A peptide leucine or valine residue is in
hydrophobic contact with P363 of subsite II. Subsite II is connected to subsite I by a
channel gated by residue M362 that separates the sub-sites.30 In this shallow channel is
bound a glycine, valine, or glutamate residue. Subsite I hosts a leucine residue buried at
the bottom of the pocket consisting of several hydrophobic residues: V360, V247 and
L177. A phenylalanine or leucine residue occupies the rear of the subsite I, allowing one
or two spacing residues between the leucine residue and the adjacent F or L residue.
Where present, the spacing residue is not involved in the binding interaction.
Recent work has shown different energetic contributions of the residues in the motif
and highlighted the role of M362 as a gating residue between the two subsites.1 The LF
portion of the motif occupies subsite I and contributes most of the energetic contribution
to peptide binding as estimated by molecular dynamics simulation and molecular
mechanics calculations.1 Previous biochemical studies suggested that the DLF tripeptide
alone is capable of binding.18
The in vivo effects of peptide-based inhibition of the SC are demonstrated by the
polypeptides from bacteriophages Twort and G1, named as TwortORF168 and
G1ORF240, the expression of which inhibited SC interactions and resulted in cell death
in Staphylococcus aureus.41 Similarly, the expression of the plasmid-borne sliding
clamp-binding peptides derived from the plasmid RK2 replication initiator protein
(TrfA) is toxic to host E. coli cells.42 It was proposed that the TrfA-derived peptides
physically interact with the SC via the N-terminal motif QLSLF.42 A deletion of the “LF”
residues in this putative SC binding motif reversed the inhibitory effect of cell growth,
DNA synthesis and filamentous phenotype.42
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Mutational studies of the residues in or adjacent to the binding pocket of the E. coli
SC have been carried out. A G157C mutation was introduced to the region close to the
binding pocket. Cells containing the mutant displayed under-initiation of replication: SC
concentration at the origin of replication was reduced.33 Mutating residues 148-152
(located in domain II near the binding pocket) to alanine impairs clamp loading and
retention on linear DNA in vitro, presumably by disrupting protein-DNA interactions.35

Figure 1.3 Superimposed crystal structures of the E. coli SC (shown in pink) in
complex with DNA Pol IV (shown in blue) (PDB entry 1UNN). The grey rectangular
square represent the binding area for the consensus motif.
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Figure 1.4 Crystal structures of the E. coli SC bound to the little finger domain of DNA
Pol IV (PDB entry 1UNN). The complexes are shown with the SC carbon atoms shaded
white and with the DNA Pol IV carbon atoms colored grey (all other atoms in CPK
colors). Dashed red lines represent H-bonds. A bridging water molecule is shown as a
red sphere.

Figure 1.5 Crystal structures of the E. coli SC bound to a C-terminal peptide from DNA
Pol IV (PDB entry 1OK7). The complexes are shown with the SC carbon atoms shaded
white and with the peptide carbon atoms colored grey (all other atoms in CPK colors).
Dashed lines in red represent H-bonds. A bridging water molecule is shown as a red
sphere.
8

Figure 1.6 Crystal structures of the E. coli SC bound with a Pol III alpha C-terminal
peptide (PDB entry 3D1E), only the peptide residues in the SC binding pocket are
shown for clarity. The complexes are shown with the SC carbon atoms shaded white
and with the peptide carbon atoms colored grey (all other atoms in CPK colors). Dashed
lines in red represent H-bonds. A bridging water molecule is shown as a red sphere.

Figure 1.7 Crystal structures of the E. coli SC bound with a Pol II-derived peptide
(PDB entry 3D1F), only the peptide residues in the SC binding pocket are shown for
clarity. The complexes are shown with the SC carbon atoms shaded white and with the
peptide carbon atoms colored grey (all other atoms in CPK colors). Dashed lines in red
represent H-bonds. A bridging water molecule is shown as a red sphere.
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Table 1.2 Crystal structures of E. coli SC (DNA Pol III β subunit) with binding partners.
Unit cell
PDB
code

Space
Group

a, b, c (Å)/α, β, γ (°)

Binding partner

Ligand binding
affinity

1OK7

P1

41.23, 65.22, 73.38/73.11, 85.58, 85.80

VTLLDPQMERQLVLGL

1.2 – 8 µM

30

1UNN

P21212

146.45, 70.12, 110.92/90, 90, 90

DNA Pol IV (243-351)

N/A

39

3D1F

P32

65.78, 65.78, 209.47/90, 90, 120

Rh6G-SEQVELEFD

1.8 µM

40

3D1E

P1

40.14, 69.87, 73.12/112.89, 91.08, 99.28

Rh6G-TLMTGQLGLF

1.7 µM

40

3BEP

P1

40.20, 70.08, 73.87/113.28, 92.07, 99.36

dsDNA, ssDNA

N/A

43

3D1G

P1

35.72, 79.39, 80.50/110.24, 100.58, 99.46

RU7

10 µM

40

3QSB

P21

79.18, 66.52, 83.12/90, 115.86, 90

Biphenyl small-molecule inhibitor

8.3 – 40 µM

44

3Q4K

P1

36.25, 80, 82.18/66.15, 74.94, 82.03

AcQChaDLpClF

0.16 – 13.9 µM

1

3Q4L

P1

34.84, 79.57, 81.64/65.28, 75.26, 82.22

AcQChaDLdiClF

0.08 – 17 µM

1

3Q4J

P1

38.09, 132.87, 137.27/62.73, 88.51, 89.77

AcQLDLF

1.1 – 1.2 µM

1
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1.3.2 Chemically modified peptides with increased SC affinity
Peptides derived from the Q1L2D3L4F5 motif (subscripts denoting position) were
developed to enhance their interactions with the SC and resulted in increased potency.1
An acetylated N-terminus (Ac0Q1L2D3L4F5) increased the IC50 (determined as the
inhibition of a fluorescently-labelled peptide binding to the E. coli sliding clamp) of the
non-acetylated form from 12 µM to 1.1 µM. Two residues were chosen by Wolff and
the co-authors for making derivatives: the leucine residue at subsite II (L2) and the
phenylalanine residue at subsite I (F5) (Figure 1.8-1.10). Since residue Q1 bound to
subsite I is conserved, and residue D3 was not expected to contribute greatly to the
affinity (as calculated by molecular mechanics) they were not modified. The authors
replaced the L2 side chain with a cyclohexyl-L-alanyl group (Cha) that occupies the
upper part of subsite II and F5 with para-chlorophenylalanine (pClF). This peptide, AcQ Cha DL pClF (Figure 1.9) has increased the affinity to an IC50 of 0.16 µM. A
similarly derivatized peptide, Ac-Q-Cha-DL-diClF (Figure 1.10), substituting the
phenylalanine benzyl ring with a 3,4-dichlorophenylalanine, increased binding affinity
to an IC50 of 0.08 µM.
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Figure 1.8 Crystal structures of the E. coli SC bound with a derivatized peptide
AcQLDLF (PDB entry 3Q4J). The complexes are shown with the SC carbon atoms
shaded white and with the peptide carbon atoms colored grey (all other atoms in CPK
colors). Dashed red lines represent H-bonds.

Figure 1.9 Crystal structures of the E. coli SC bound with a derivatized peptide AcQCha-DL-pClF (PDB entry 3Q4K). The complexes are shown with the SC carbon atoms
shaded white and with the peptide carbon atoms colored grey (all other atoms in CPK
colors). Dashed red lines represent H-bonds. A bridging water molecule is shown as a
red sphere.
12

Figure 1.10 Crystal structures of the E. coli SC bound with a derivatized peptide AcQCha-DL-diClF (PDB entry 3Q4L). The complexes are shown with the SC carbon atoms
shaded white and with the peptide carbon atoms colored grey (all other atoms in CPK
colors). Dashed red lines represent H-bonds. A bridging water molecule is shown as a
red sphere.
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1.3.3 ssDNA occupies part of subsite I
The first dsDNA-bound SC structure was revealed by Georgescu and coworkers.43
The DNA used in crystallization experiments contains a section of ssDNA that interacts
with the previously described SC binding pocket in a symmetry-related SC molecule.
The authors argued that the SC binding to the template ssDNA may serve to hold the
clamp at a primed site after loading, or during switching of multiple factors on the
sliding clamp.43 The ssDNA template makes extensive interactions with the residues
close to the binding pocket (Figure 1.11). Many interactions are beyond the edge of the
binding pocket, which are not observed in the peptide-bound structures (Figure 1.41.10). Three dT nucleic acid residues (dT11-dT13) interact with subsite I primarily
through hydrogen bonding: dT11 with T172 sidechain, dT12 with R245 and R240 side
chains and D243 backbone NH group, and dT13 with R240 backbone carbonyl group
(Figure 1.11). It is noteworthy that the two arginine residues also engage in cation-π
interactions with the nucleobases.
1.3.4 Small molecule inhibitors developed to date
Small molecule inhibitors of the SC peptide-binding pocket reported to date are
found to bind in subsite I40,44 (Figure 1.12). They overlap with the aforementioned
peptide-L4F5 motif when the SC structures are superimposed, and share one common
feature: a halogenated phenyl ring.40,44
RU7, a small-molecule inhibitor discovered by Georgescu and co-workers40 from a
high-throughput screen, occupies subsite I. A bromine atom forms a halogen bond with
the T172 side chain (Figure 1.12). The other parts of the RU7 are mainly stabilized by
hydrogen bonds that are similar to the ssDNA-binding pattern (Figure 1.11). The IC50
14

of RU7 was 10 µM as measured using a fluorescence polarization anisotropy-based
assay.

A recently described biphenyl compound44 occupies the all of subsite I,

presumably with favourable desolvation entropy due to its hydrophobicity (Figure 1.12).
Its IC50 was determined to be around 40 µM in a plate-binding assay and 8.3 µM in an
SPR-based assay.
No small molecule inhibitors reported to date occupy both subsites. This is possibly
due to the spatial separation of subsite I and II, the steric hindrance from the side chain
of M362, and the rigidity of the compounds’ ring structures.
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Figure 1.11 E. coli SC with a ssDNA motif at its recognition site (PDB code 3BEP). The atoms of binding pocket subsites (I and II) are
presented in green with electrostatic surface display, the ssDNA in grey. Non-carbon atoms are CPK colored. Protein structure is presented with
ribbon diagram colored by secondary structure (Pink: β-sheet, Light blue: α-helix and White: others).
16

Figure 1.12. E. coli SC bound with RU7 (light blue) and a biphenyl compound (pink), respectively. The structures are colored accordingly. Noncarbon atoms are CPK colored. Hydrogen bonds and a halogen bond are presented as red dashed lines.
17

1.4 Small molecule intervention of protein-protein interactions (PPI)
The largest class of currently marketed small-molecule drugs target G-proteincoupled receptors, nuclear receptors, ion channels and enzymes. They are competitors
of natural ligands, which are often small molecules themselves.45 However, there is
increasing clinical need for a variety of drug interventions in many diseases for which
conventional therapeutics fail to be effective.46 Protein–protein interactions (PPIs) are
key to numerous biological processes such as cell cycle control, apoptosis,
differentiation and signalling pathways. It has been shown that PPIs are disrupted in
many diseases and can be potential targets for therapeutic intervention.47,48 It has been
proposed that large-scale genomic and proteomic studies of protein-protein interaction
networks within cells will identify a variety of therapeutic targets from various
biological pathways.49 PPIs have been proposed to represent a novel class of targets for
the development of new therapeutic drugs.50,51
Targeting PPIs is considered to be more difficult than small molecule-binding sites
since PPI interfaces are relatively large, less conserved, often flexible and flatter when
compared with small-ligand binding pockets.52-56 Thereby comes the dilemma that
drugs should be small enough to penetrate the cell and also be able to affect the
relatively large surface area at PPI interaction sites. Small molecules were considered
unlikely to be effective PPI inhibitors until evidence emerged showing that small
molecules do not have to cover the entire PPI interface, but rather only bind to a
“hotspot” that contributes the most to the binding free energy of the PPI.57-61 Hotspots
comprise relatively small fraction of PPIs, and are usually found at the centre of the
interface. In such cases, small molecules may act as effective PPI inhibitors.62-64
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Targeting ‘promiscuous’ proteins that bind to several targets using the same hotspot
region can be problematic, as the contact surfaces are adaptable, allowing one protein to
bind to a range of structurally diverse partners.65 Furthermore, high-throughput
screening (HTS) performs less well at identifying compounds that disrupt protein–
protein interfaces compared with enzymatic targets since the composition of the
compound libraries are frequently biased toward enzymatic inhibitors.66,67

Despite efforts made to date, there are relatively few reports of protein structures in
complex with small molecule inhibitors that disrupt PPIs compared with other drug
classes. PPI inhibitors are often relatively large (compared with other drug classes),
rigid molecules, containing hydrophobic and aromatic rings.53,54 Beside empirical
approaches, currently there are no generally applied structure-based approaches for the
discovery of PPI inhibitors. Many approaches so far have focused on discovering
druggable PPIs by in silico screening of small-molecule libraries and searching the
chemical space of PPI inhibitors. Molecular dynamics simulations and protein-ligand
docking studies may reveal the dynamic nature and physicochemical properties of
protein–protein/protein-ligand complexes to identify a thermodynamically stable pocket,
i.e. the “hotspot” that can be targeted in small-molecule library screenings.68
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1.5 A fragment-based approach applied to PPI inhibitor design
1.5.1 What is fragment-based design?
Implicit in the lead discovery and optimization stages in drug design is the idea that
molecules are modular: each molecular fragment contributes specific properties to the
drug candidate as modules that can be combined while retaining their binding poses and
specific binding interactions. Researchers have relied on the modular nature of
molecules since the early days of drug discovery. Functional groups are swapped
between candidates to improve overall affinity and alter some other property of the
molecule to increase drug-like characteristics such as lipophilicity.
Currently, many in silico methods for prediction of molecular properties have been
based on the decomposition of molecules into their parts to develop predictive models.69
Fragment-based techniques were pursued in the prediction of some physiochemical
properties such as logP, and several biological characteristics including toxicity70,71. In
recent years, fragment analysis has made contributions to the discovery and
optimization of lead molecules and to the prediction of various chemical properties.
This has generated great interest as an alternative paradigm for drug discovery72,73 for
reasons outlined below.
1.5.2 Why use a fragment-based approach?
Traditional antibiotic discovery involved natural product screening. Early
advancements include high-throughput screening and combinatorial chemistry.
Advancements in biochemistry and molecular biology allowed molecular targets to be
identified, cloned and produced by recombinant DNA methods. Analytical biochemical
approaches with automation tools became widely available.74 However, these
technologies did not live up to expectations with respect to the discovery of new
20

antibiotics, since major pharmaceutical libraries for high-throughput screening are
designed

principally

for

enzymatic

targets

within

eukaryotic

cells.75

The

physicochemical properties of the would-be antibiotics that enable both penetration of
prokaryotic membranes and binding to non-enzymatic targets may differ from those of
the agents active against eukaryotic targets.76 Fragment-based design is not biased
toward any particular target. The emphasis is on functional diversity with relatively
small libraries, typically fewer than 1000 fragments.
Although the specificity and potency of the fragments are poor compared to
lead/drug-like compounds (since fragments lack structural complexity), the hit-rates and
chemical distinctiveness with fragments are higher. Therefore they serve as good
starting points for lead development.77
1.5.3 How is fragment-based screening performed?
The first examples of fragment-based screening utilised cocktail crystallography78,
i.e., cocktails of fragments were soaked into crystals and their X-ray structures
determined. However, the use of crystallography to screen for active fragments limits
the size of the libraries that can be screened, albeit having the advantage of supplying
immediate structural information for hits.79 This may result in many potential hits being
missed due to the dual requirement to satisfy the conditions for weak binding and
crystal formation. Other screening methods such as NMR80, surface plasmon resonance
(SPR),81 and higher-throughput, high-sensitivity biochemical screening methods such as
fluorescence correlation spectroscopy (FCS)82 and weak affinity chromatography
(WAC)83 are also used to screen for bound fragments. The combination of biochemical
screening and NMR-based screening provides a particularly effective approach for the
discovery of fragment hits.84,85 There has also been interest in the use of mass
21

spectrometry or isothermal titration calorimetry (ITC) in FBDD screening.86,87 All of
these techniques can be used to confirm the hits from one of the screening methods. Xray crystallography is usually a vital part of the fragment-to-lead and lead-optimization
process following the discovery of a fragment hit.88
1.6 Scope of this study
The overall aim of the study is the design of small-molecule inhibitors as potential
drug leads against bacterial SC. Since medicinal design often require in-depth
understanding of the drug target when interacting with its physiological binding partners,
the work presented in this thesis begins with the delineation the nature of peptides
binding to the E. coli SC as its natural ligands. Using biochemical, biophysical, and
structural evidences as well as theoretical approach, a model was proposed to account
for the binding events.

This model of receptor-ligand interaction reveals a “hot-spot” on the E. coli SC
favorable for ligand binding. Focusing on the “hop-spot” identified, fragment-based
screening targeting the E. coli SC using X-ray crystallography was carried out. Initial
hits were then identified binding to the “hot-spot”.

The model also defines the binding areas beyond the “hot-spot” and subsequent
development after the fragment-based screening were carried out, which led the
development of high-affinity small-molecular inhibitors of the E. coli SC with expanded
binding area beyond the “hot-spot”.
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Chapter 2
General Materials and Methods.
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2.1 Protein over-expression
Protein production and purification followed the published protocol.36 Briefly, E. coli
strain AN1459 carrying plasmid pND261 carrying a bacteriophage λ-promoter was
grown in 6 L of LB medium with 50 mg each of thymine and ampicillin at 300 K for 5
hours and moved to a water bath pre-heated to 315 K. After a 3-hour incubation, the
culture was centrifuged and the pellets were collected and stored at 253K.
2.2 Protein purification
The pellets were thawed and resuspended in 100 mL lysis buffer (50 mM Tris-HCl,
pH 7.6, 1 mM EDTA, 1 mM DTT and 20 mM spermidine) and passed twice through a
French press (82.7 MPa). PMSF (1 mM) was added to the homogenate, which was
centrifuged at 15,000 rpm for 30 min; ammonium sulfate was added to the supernatant
(0.32 g/mL), stirred on ice for 30 min and centrifuged at 15,000 rpm for 30 min. The
pellets were then re-dissolved in 50 ml buffer A (50 mM Tris-HCl pH 7.6, 1 mM EDTA,
1 mM DTT) and centrifuged to remove insoluble material. The solution was dialyzed
against 2 L buffer A with 0.17 M NaCl and passed at 5 ml/min through a column (2.5 x
20 cm) of Toyopearl TSK DEAE-650M anion exchange resin equilibrated with the
same buffer. The flow-through was collected, dialyzed against 2 L of buffer A and
loaded onto the same column pre-equilibrated with the same buffer. After washing the
column with 100 ml buffer A, the column was washed with buffer A with 200 mM
NaCl and the SC was eluted as a single sharp peak. The elution was collected and
dialyzed against 2 L buffer B (20 mM sodium phosphate pH 6.5 and 1 mM DTT) and
then passed at 2 mL/min through a column (2.5 x 15 cm) of hydroxyapatite (BioRad)
pre-equilibrated with buffer B. The SC was eluted in a linear gradient of 20-200 mM
sodium phosphate (pH 6.5). The purity of the β SC was then checked with SDS-PAGE
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and precipitated with ammonium sulfate (0.5 g/mL) and dialyzed against storage buffer
(20 mM Tris-HCl pH 7.2, 0.5 mM EDTA, 1 mM DTT and 15% (v/v) glycerol).
2.3 Nanoelectrospray ionization (ESI) mass spectrometry (MS)
The accurate molecular mass of purified SC protein was analysed after purification
using ESI-MS, which can be accurate to <0.01% of the total molecular mass of the
protein. A Waters ESI-Q-TOF Ultima mass spectrometer was used for nanoelectrospray
ionization mass spectrometry. The SC was dialyzed against 100 mM ammonium acetate,
pH 7.2 and was tested at concentrations of 1 to 10 µM. The SC was injected into a goldcoated capillary needle. The capillary voltage was 1.5 kV, the cone voltage was 35 V
and RF lens was 175 V. Data were collected over the mass range 2000-8000 m/z (100
acquisitions, 2s each). The spectra were analysed using Masslynx™ and further
processed with GraphPad Prism.
2.4 Protein crystallization
The SC stock solution contains the SC at 53 mg/mL in 20 mM Tris-HCl pH 7.2, 0.5
mM EDTA, 1 mM DTT and 15% (v/v) glycerol.Crystals of the SC were grown at 285 K
by the hanging-drop vapour diffusion method. The hanging drop was composed of 1 µl
of SC stock solution mixed with the same volume of a reservoir solution composed of
100 mM MES pH 6.5, 100-150 mM CaCl2 and 25-30% (v/v) PEG400. The reservoir
volume was 1 mL. Ligands were pre-dissolved in DMSO at 10-100 mM and soaked into
the crystal at the final concentration of 2-5 mM with < 10 % (v/v) DMSO.
2.5 X-ray data collection
Procedures for cryo-protection of the protein crystals were exempted as the reservoir
contains ~30% PEG400, which is sufficient for cryo-protection upon freezing.
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All crystals were mounted onto MiTeGen™ loops on pins with magnetic caps. For
in-house data collection, crystals were flash-frozen to 100 K using an Oxford Cryostream. Diffraction data were collected using a MAR345 desktop beamline using CuKα
X-ray from a Rigaku 007HF rotating anode generator with Varimax™ optics. Frames
were collected for each crystal with 1° increment. Exposure times ranging from 2 to 5
min were used.
For synchrotron data collection, the SSRL Automated Mounting system (SAM) was
used. Mounted crystals were flash-frozen in liquid nitrogen and placed in the SAM
cassettes. Diffraction data were collected at the Australian Synchrotron, Beamline MX1
using X-rays of wavelength 0.95 Å.
2.6 Data processing, structural solution and refinement
Crystal data sets were integrated, merged and scaled with either HKL200089 or
MOSFLM and SCALA of the CCP4 software package.90 The structures were solved by
molecular replacement with MOLREP91 using the Protein Data Bank entry 1MMI (an
apo-crystal of E. coli SC of space group P21) as a starting model.36 All waters, ions and
ligands were removed before molecular replacement. Iterative model building and
refinement was done with COOT92 and REFMAC593. Electron density maps
(2mFo−DFc and mFo−DFc) were calculated using structure factor amplitudes and phase
angles derived from REFMAC5. Water molecules, ions and PEG fragments observed in
the electron density map were added to the model using COOT92. In case residues
and/or ligands demonstrated poor electron density, occupancies of corresponding atoms
were adjusted accordingly. Geometric restraints for ligands without library description
were prepared using Monomer Library Sketcher of CCP4 software package90 or an
online server PRODRG (http://davapc1.bioch.dundee.ac.uk/cgi-bin/prodrg ).
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Chapter 3
Structural and thermodynamic elucidation of
linear motif recognition
by the E. coli sliding clamp
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3.1 Introduction
Protein-protein interaction sites govern numerous biological processes and are a
well-known class of drug target.94 Linear motifs (LMs) are short (4-10 residues)
intrinsically disordered sequences that are often found at the termini of proteins and
sometimes in loop regions.95-97 Recognition of LMs98,99 by rigid protein domains
represents a distinct category of protein-protein interaction, with many examples
involved in cell signaling, DNA replication and other cell-regulatory processes.100-102
Recognition of LMs by their partner proteins often show both specific and promiscuous
characteristics.103 Promiscuity arises because the protein acts as a binding “hub” capable
of interacting with multiple partners bearing distinct (but related) LMs.103,104 Specificity
arises from the interaction of conserved LM “anchor” residues105-107 with target receptor
“hot spots”108,109 which when removed lead to loss of binding affinity. In general, LM
recognition events are transient and show only weak affinity (1–100 µM)110 and it has
been proposed that this may arise from the configurational entropy loss that occurs
when LMs adopt the bound conformation.111 This is supported by the fact that most LM
peptides do not induce conformational changes in their binding partners.109
Hydrophobic residues commonly found in LMs are also thought to contribute
entropically favorable desolvation free energy to the binding.96,112,113 A sequential
model of LM-binding via partially bound states has been proposed and is consistent
with the typically observed fast on-and-off binding kinetics.105,106,114
While there is growing interest in the design of drugs targeting LM-recognition
sites115,116 these efforts are being hampered by a lack of further mechanistic insights into
the binding process. Additional structural evidence in support of the sequential binding
model is required along with further evidence connecting LM characteristics with their
dynamic behavior.
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As described in Chapter 1, the E. coli SC is a protein-protein interaction hub for
consensus LMs of various binding partners. The LMs of SC partner proteins are usually
found at their N- or C-termini and these isolated peptides tend to bind to the SC with
affinities similar to their parent proteins.38,44 Conversely, when LMs are removed the
truncated proteins lose all binding affinity.18,42 Previous studies have shown that the
consensus motif (QLx1Lx2F/L: S/D preferred at x1, x2 may be absent) binds to a specific
pocket on the SC monomer comprised of two subsites, I and II.30,40 A pentapeptide
derived from the consensus motif, Ac0Q1L2D3L4F5, binds to the SC with equivalent
affinity to SC-binding proteins (Kd ~ 1 µM ). It is considered to be the minimal binding
motif.1,40,117
As described in this chapter, a combination of biochemical/biophysical assays and
structural and theoretical approaches have been used to gain key mechanistic insights
into E. coli SC-LM recognition. Single-residue substitutions of the Ac0Q1L2D3L4F5
consensus peptide were used to characterize the binding determinants and to elucidate
the structural basis for the specificity of LM-binding. The weak and transient nature
typical of LM recognition was computationally probed with supporting evidence
provided from calorimetric data. The study has led us to propose a sequential binding
model wherein the anchor residues of the LM establishes initial contacts with subsite I
which is then followed by binding of the flanking residues to subsite II. The model is
supported by steered molecular dynamics (SMD) simulations and crystal structures
which

provided

snapshots

into

the

sequential

binding

pathway.

The

desolvation/resolvation profile of almost-buried polar atoms (ABPA)118 is shown to
account for the priority of anchor-residue positioning over positioning of other residues
in the LM.
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3.2 Materials and Methods
3.2.1 Fluorescence polarization assay
All FP experiments were conducted with a POLARstar Omega plate reader using
non-treated black sterile 96-well plates (Greiner, USA). The buffer contains 10 mM
HEPES (pH 7.4), 1 mM EDTA, 1 mM DTT, 0.07% (v/v) Nonidet P-40 and 5% (v/v)
DMSO. Various fluorescently-labelled peptides were designed and tested. One
fluorescent peptide, 5’-fluorescein (FAM)-QLDLF-OH (GL Biochem, China) with > 95%
purity confirmed by the manufacturer using HPLC-MS, was used for the competition
assay with 10 nM of tracer and 50 nM of the SC monomer. Blank control (buffer),
negative control (buffer and the peptide) and positive control (buffer, peptide and the
sliding clamp) were used for data standardization to yield the extent of inhibition.
Experiments were carried out in duplicate. Curves were fitted using GraphPad Prism
v5.01 (GraphPad Software, USA). Binding-saturation curve fitting was applied to tracer
binding. Dose-response curve fitting was applied to competition assays with variable
slope, constraining Top at 100 and Bottom at 0.
3.2.2 Isothermal Titration Calorimetry
ITC was performed using a MicroCal Auto-iTC200 calorimeter (Microcal, GE
Healthcare) at 298 K. The SC was dialyzed against a buffer (10 mM HEPES pH 7.2,
0.15 M NaCl and 1 mM EDTA) and the same buffer was used to dissolve the peptides.
The feedback mode was “high” with the reference power setting of 10 µcals-1. The cell
was stirred at 1000 rpm and the thermostat was set to 25 °C. Experiments were
conducted with 19 injections of 2 µL of the mixture over 4s with 200s spacing. The first
injection of 0.4 µL was discarded in all cases. Peptides of 2-5 mM were titrated in
sequential injections (2 µL each) into 54 or 90 µM SC monomer. Data were corrected
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for control experiments with peptide titrated into buffer only. Data analysis was carried
out with Origin 7.0 using one-site binding data fitting.
3.2.3 Molecular dynamics simulation, molecular mechanics calculation
Molecular dynamics simulations were performed with the Amber11 software
package.119 The starting coordinates were extracted from the complex crystal structures
SCAcALDLF, SCAcQADLF, SCAcQLALF, SCAcQLDAF and SCAcQLDLA and SCAcQLDLF(PDB entry
3Q4J1). A simulation of native SC was performed using the apo crystal structure
determined in space group P21 (PDB 1MMI36). Monomers with domain I (residues 1125) removed were used in all cases due to the software limitation on normal mode
analysis when processing large systems. Thus, truncated SC monomers (residue range
126 to 365, domain III truncated) with peptide ligands (except for the native sliding
clamp) were simulated.
To prepare coordinates for simulation, crystallographic waters > 3.5 Å away from
any protein atoms were deleted. Hydrogen atoms were built and partial charges assigned
using xLeap (ff99SB force field). To the resulting system, TIP3P molecules were added
to form a rectangular box with edges a minimum of 10 Å from the solute. The system
was subjected to energy minimization in two stages, first with 10 kcal/mol/Å2 harmonic
restraints on the solute and crystallographic waters and then with the restraint removed.
Each stage consisted of 2500 steps of steepest descent and 2500 steps of conjugate
gradient energy minimization. The system was then heated from 0 to 300 K in 20 ps
with the 10 kcal/mol/Å2 harmonic restraints on the solute and crystallographic waters (at
constant volume), equilibrated at 300 K for 50 ps with 2 kcal/mol/Å2 restraint on the
protein (at constant pressure) and then equilibrated at 300 K for 50 ps without harmonic
restraint under constant pressure (1 atm, using isotropic positional scaling). For all MD
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runs, the Langevin temperature control algorithm was used with a time constant and
collision frequency of 2.0 ps. Production runs (10 ns) were performed with PMEMD.
The non-bonded cut-off was set to 10 Å. The SHAKE algorithm was used to constrain
all bonds to hydrogen atoms. An integration time-step of 2 fs was used and atomic
coordinates were saved every 1 ps for analysis. The PTRAJ program was used for
calculation of root mean square fluctuations and radial pair distributions. Simulations of
peptides in explicit water were carried out using the same protocol but with production
runs extended to 50 ns. Subsequent MM-PBSA calculations and normal mode analyses
of trajectories were carried out on each complex using the MMPBSA module. MMPBSA calculations were done to coordinate snapshots 10 ps apart with ionic strength set
at 0.1 M. Single trajectory calculations were performed to avoid errors introduced due
to insufficient sampling of such a large system. Separate calculations were performed
on peptides bound to the SC and in water. Normal mode calculations of configurational
entropy used a triple trajectory approach with the calculations performed on the
complex, and on the SC and ligands in isolation. Snapshots 200 ps apart were extracted
and calculated.
3.2.4 Steered molecular dynamics simulations
SMD simulations were carried out with the AMBER 11 package119 using published
methods.118 A total of three systems were simulated. For the first two, starting
coordinates were taken from the SCAcQLALF and SCAcLF complex crystal structures. The
coordinates of the third system (the SC in complex with AcQL) were modelled using
the SCAcQLALF complex structure.
All residues of the SC or crystallographic waters beyond 12 Å of the
AcQLALF/AcQL/AcLF ligands were deleted. The three truncated systems were
neutralized and TIP3P water molecules were added, extending 18 Å out from the
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dimension along which the pulling forces were to be applied, and 10 Å extending from
the other two dimensions.
All three systems were subject to 2500 steps of steepest descent energy minimization,
followed by 2500 steps of conjugate gradient energy minimization. Harmonic restraints
(10 kcal/mol/Å2) were placed on the solute. Another 5000 energy minimization steps
followed with the same restraints applied to the backbone atoms (Cα, C, O, N). The
systems were then heated from 0 to 300 K in 20 ps with the same restraint and at
constant volume, then equilibrated at 300 K for 50 ps with harmonic restraints (10
kcal/mol/Å2) on the solute. Another 50 ps equilibration run followed with harmonic
restraints (10 kcal/mol/Å2) on the backbone atoms (Cα, C, O, N). Equilibration runs
were done under constant pressure. A 10 ns production NPT run was performed with
PMEMD. The non-bonded cut-off was set to 10 Å. The SHAKE method was applied to
constrain all bond lengths involving hydrogen atoms. The temperature control was
based on the Langevin algorithm with a time constant and collision frequency of 2.0 ps.
The pressure was kept at 1.0 atm using isotropic positional scaling. An integration step
of 2 fs was used and coordinates were saved every 1.0 ps.
A total of 20 snapshots spaced 500 ps apart were extracted from each production run
trajectory and subjected to 1 ns SMD simulation each. In each SMD simulation, the
ligands were pulled for 6 Å (in cases of AcQL/AcLF) or 15 Å (in the case of AcQLALF)
from the binding pocket. The pulling forces were applied to the centre of mass of the
receptor Cα atoms and the heavy atoms of the ligand. The pulling of AcQLALF was
performed three times with the force applied on the AcQL- sub-motif, the -LF sub-motif
or the entire peptide. The pulling distance was used as the reaction coordinate with 5000
kcal/mol/A2 force constant. All backbone atoms of the receptor were restrained with 10
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kcal/mol/Å2 harmonic restraints during the SMD simulation. Other parameters of SMD
simulation followed the same protocol as was used in the production runs. The
cumulative work measured along the reaction coordinates were Boltzmann-averaged
using the Jarzynski relation.120 The Jacobian correction121 was then applied and the
cumulative work was standardized by subtracting the initial value. The distances and the
numbers of water contacts were calculated with PTRAJ for each SMD simulation
trajectory and Boltzmann-averaged as described.118
3.3 Results and discussion
3.3.1 Fluorescence polarization assay development
3.3.1.1 Design of fluorescently labelled tracers
The fluorescently-labelled tracers were designed based on the sequence of the
consensus motif (QLDLF). Two fluorescent peptides were designed by fusing a 5fluorescein to the consensus motif: AcQLK(5FAM)LF-OH with the 5-fluorescein fused
to the lysine residue in the middle of the sequence and 5FAM-QLDLF-OH with the 5fluorescein fused at the N-termini of the sequence. The former was designed to avoid
possible reduced affinity that might occur through the disruption of the positioning of
the N-terminal residues, in this case the glutamine residue.
Both tracers were obtained and tested at 10 nM, around which concentration the
tracer is usually used in fluorescence polarization-based assays.122,123 Their bindingsaturation curves were plotted (Figure 3.1) against the receptor (the SC monomer)
concentration. The 5FAM-QLDLF-OH showed superior binding properties as the
AcQLK(5FAM)LF-OH did not reach complete saturation even with very high receptor
concentration. Therefore the 5FAM-QLDLF-OH was chosen as the tracer to be used in
inhibition assay.
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3.3.1.2 Characterization of the fluorescent tracer
As the primary assay used in peptide/inhibitor testing and IC50 determination, it was
necessary that the assay was both sensitive and robust. Since DMSO is used to dissolve
both peptides and compounds to make stock solutions, the assay system was tested for
DMSO tolerance by titrating the SC of various concentrations into the buffer system
containing 10 nM tracer and various DMSO concentrations (0%, 5% or 10%). DMSO at
three concentrations was tested, and DMSO at up to 10% (v/v) did not significantly alter
the binding-saturation curve (Figure 3.2). Therefore 10% (v/v) DMSO was chosen for
the buffer condition which is tolerated by the SC-tracer binding.
The affinity (dissociation constant, Kd) was calculated using a binding-saturation
curve taking ligand depletion into account.124,125 The dissociation constant of the tracer
was determined to be 70 nM (Figure 3.3), tighter that that estimated for AcQLDLF (Kd
~ 1 µM). This could be due to the 5-fluorescein on the N-terminus of the tracer peptide
having an interaction with the SC and contributing positively to the binding affinity.
3.3.1.3 Inhibition assay design
The fluorescent tracer (10 nM) with the SC as the receptor (50 nM) was used in the
competition/inhibition assay to determine the IC50 of the inhibitors (either peptides or
synthetic compounds). The receptor concentration was near the Kd of the tracer-receptor
system allowing sensitive analysis of inhibitory interactions.
To validate the inhibition assay, the AcQLDLF peptide was used as the reference,
which was previously reported as a tight binder with Kd ~ 1 µM affinity.1 The extent of
inhibition (% Inhibition, Figure 3.4) of the tracer binding to the receptor was calculated
from the milli-polarization (mP) values using the generally applied equation for
standardization.126 The extent of inhibition was plotted against the inhibitor
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concentration and the IC50 value was calculated by fitting the curve to a dose-response
curve with variable slope. The AcQLDLF peptide inhibited the tracer binding to the
receptor with an IC50 value of 1.85 µM (Figure 3.4). This value can be further
transformed into a Kd (or Ki) value using the Kenakin correction for ligand depletion.127
Here, the ligand depletion refers to the depletion of the tracer when >10% of the tracer
is bound to the receptor, and the effective tracer concentration is significantly reduced
which causes an underestimation of the actual affinity. In the case of AcQLDLF peptide
as the inhibitor, its Kd after Kenakin correction is 0.9 µM. This corrected value is
similar to the reported affinity of ~1 µM.
These procedures were applied to all FP inhibition assays described here.
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Figure 3.1 Binding-saturation curves of the SC titrated into two fluorescently labelled
peptides at 10 nM. Curves were fitted to one-site binding model taking into account of
ligand depletion. Error bars represent ± 1 standard deviation (n=2). Where not visible,
error bars are within the markers.
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Figure 3.2 Binding-saturation curves of the SC titrated into the fluorescent tracer with
various amounts of DMSO in the buffer. Curves were fitted to one-site binding model
taking into account of ligand depletion. Error bars represent ± 1 standard deviation
(n=2). Where not visible, error bars are within the markers.
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Figure 3.3 Binding-saturation curves of the SC titrated with the fluorescent tracer.
Curves were fitted to one-site binding model taking into account of ligand depletion.
The calculated dissociation constant (Kd) is shown. Error bars represent ± 1 standard
deviation (n=2). Where not visible, error bars are within the markers.
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Figure 3.4 Dose-response curve (with variable slope) of the reference peptide titrated
with 50 nM SC pre-mixed with 10 nM of the fluorescent tracer. The calculated IC50
value for the inhibition relating to the tracer binding to the SC is shown. Error bars
represent ± 1 standard deviation (n=2). Where not visible, error bars are within the
markers.
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3.3.2 Interactions of Q1 with subsite II and L4F5 with subsite I
The published X-ray crystal structure of the consensus pentapeptide Ac0Q1L2D3L4F5
in complex with the E. coli SC (PDB entry3Q4J)1 is shown in (Figure 3.5). In this
structure the N-terminal Ac0Q1L2 dipeptide sub-motif occupies subsite II making three
H-bonds to the backbone of M362, P363 and R365, and one H-bond to a bridging water
molecule (W0). The side chain of L2 is involved in hydrophobic interactions with P363.
The non-polar C-terminal L4F5 dipeptide sub-motif occupies subsite I and makes
interactions with the hydrophobic side chains of L177, V247, V360 and M362. In the
current work, X-ray crystal structures of the SC were obtained in complex with all five
possible alanine mutants of the consensus peptide; AcA1L2D3L4F5, AcQ1A2D3L4F5,
AcQ1L2A3L4F5, AcQ1L2D3A4F5 and AcQ1L2D3L4A5 (Complexes are denoted SCAcALDLF,
SCAcQADLF, SCAcQLALF, SCAcQLDAF and SCAcQLDLA; Figure 3.5 B–F. Crystallographic
data are provided in Table 3.1). The individual structures are discussed below in the
context of their SC binding affinities.
The binding contribution of each residue in Ac0Q1L2D3L4F5 was probed using a
systematic series of mutant peptides (Table 3.2). Binding affinities for the mutants were
measured using a fluorescence polarization (FP) assay employing a fluorescentlylabeled tracer peptide (Kd = 70 nM, determined with binding-saturation curve fitting).
Inhibition of tracer binding to the SC was plotted against peptide concentrations and
their IC50 values calculated and transformed into Kd using the Kenakin correction for
ligand depletion (Table 3.2).127
The acetylated N-terminus (Ac0) of AcQLDLF mimics the main-chain of LMs in
providing a carbonyl oxygen to accept an H-bond (Figure 3.5A). Replacing Ac0 with a
charged primary amine at the N-terminus significantly decreased affinity (Table 3.2).
Replacing Q1with glutamate increased Kd significantly but changing to asparagine led
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only to a modest increase. Reducing Q1 down to alanine or glycine greatly reduced
affinity and this change also precluded correct positioning of the Ac0A1L2- sub-motif, as
evidenced by the lack of electron density in the map of the SCAcALDLF complex (Figure
3.5B). These findings establish the crucial importance of the two H-bonds formed from
the Q1 side chain for binding in subsite II.
Replacing the hydrophobic residue L2 with valine, alanine or glycine had a less
dramatic effect on binding than changes at Q1, while substituting D3 for alanine or
glycine had almost no effect. Additionally, replacing L2 or D3 with alanine did not alter
the bound peptide conformations relative to the consensus sequence (Figure 3.5C, D
relative to A).
Substitution of L4 with valine had a strongly detrimental effect on binding,
highlighting the strict steric requirements for binding in this region of subsite 1.
Replacing L4 with alanine significantly reduced affinity as well as crystallographic
ligand occupancy, as evidenced by the poor peptide electron density in the SCAcQLDAF
complex (Figure 3.5E). A glycine residue at this position further reduced affinity. The
significant difference in binding energy observed for the alanine- versus glycinesubstituted peptides at position 4 (ΔΔΔG = 1.08 kcal/mol; Table 3.2) may be due to the
higher flexibility of glycine. This increased flexibility would impose a larger entropic
cost upon binding and reduce the likelihood of G4F5 binding in subsite I and triggering
subsequent subsite II binding events (see sequential binding model below).
Replacement of F5 with leucine produced a modest increase in Kd, but when replaced
with alanine or glycine there was a detrimental effect on binding that was similar to the
same substitutions at the L4 position. Interestingly, the SCAcQLDLA complex structure
(Figure 3.5F) showed that replacement of F5 with alanine causes this residue to be
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flipped out of subsite I leaving half of the subsite unoccupied. This is consistent with a
sub-motif (e.g. L4F5) needing to fully occupy subsite I before binding interactions are
triggered in subsite II (see sequential binding model below).
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Figure 3.5. Crystal structures of the E. coli SC bound toAc0Q1L2D3L4F5 consensus
peptide (SCAcQLDLF, A)1 and its alanine mutants: SCAcALDLF (B), SCAcQADLF (C),
SCAcQLALF (D), SCAcQLDAF (E) and SCAcQLDLA (F). The complexes are shown with the
SC carbon atoms shaded white and with the peptide carbon atoms colored grey (all
other atoms in CPK colors). Electrostatic potential surfaces of the binding site are
shown with blue = positive and red = negative. Dashed lines in red represent H-bonds.
A bridging water (W0) is shown as a red sphere. Electron density maps (mFo–DFc)
contoured at 3σ are shown in green wire-basket form.
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Table 3.1. Data collection and refinement statistics of E. coli SC in complex with
AcALDLF, AcQADLF, AcQLALF, AcQLDAF, AcQLDLA, or AcLF.
Name
SCAcALDLF
SCAcQADLF
SCAcQLALF
PDB Code

4K3M

4K3O

4K3P

Data collection
Space group

P21
a, b, c (Å)/α, β, γ (°)

a, b, c (Å)/α, β, γ (°)

a, b, c (Å)/α, β, γ (°)

79.85, 67.29, 81.19 /
90.00, 113.75, 90.00

79.98, 67.24, 81.43/
90.00, 113.78, 90.00

79.96, 66.68, 80.92 /
90.00, 114.16, 90.00

Resolution (Å)

50.00-1.85(1.92-1.85)

50.00- 2.00 (2.07-2.00)

73.83 - 2.15 (2.27-2.15)

Rmerge (%)

3.8(31.6)

2.8 (21.8)

6.9(41.1)

No. of Reflections

247402

131408

118432

Unique Reflections

Mean I/σ(I)

66828 (6455)
7.9 (3.1)

48290 (4496)
31.1 (3.7)

38882 (5440)
9.7 (2.2)

Completeness

99.3 (96.9)

89.5 (84.3)

91.7 (88.5)

Multiplicity

3.7 (3.1)

2.6 (2.5)

3.0 (2.8)

30.65 -1.85 (1.90-

21.36 -2.00 (2.05-

49.49 - 2.15 (2.20-

Cell dimensions

Refinement
Resolution (Å)
Rwork/Rfree
R.m.s
Bond lengths
Å
Bond angles
(º)

20.2(27.8)/25.8(37.3) 19.9(22.4)/24.8(32.9) 22.3(30.7)/27.3(36.4)
0.007

0.005

0.006

1.145

1.114

1.133

M. Chain

17.4

24.4

31.3

S. Chain &

21.6

28.0

33.7

Ligands**

29.5

29.5

36.1

B-factors

Ramachandran
0.29%
0.28 %
0.43 %
Plot Outliers
The value for the highest resolution shell is given in parenthesis. Diffraction data
collected at home-sourced X-ray generator at the wavelength of 1.5418 Å. Diffraction
data for SCAcQLALF and SCAcQLDLA were processed with MOSFLM and SCALA while
others were with HKL2000.
* Diffraction data collected at BeamlineMX1, Australian Synchrotron, at the
wavelength of 0.95 Å; **Ligands refer to the short peptides/analogues.

43

Table 3.1 (continued). Data collection and refinement statistics of E. coli SC in
complex with AcALDLF, AcQADLF, AcQLALF, AcQLDAF, AcQLDLA, or AcLF.
Name

SCAcQLDAF

SCAcQLDLA

SCAcLF*

PDB Code

4K3Q

4K3R

4K3L

Data collection
Space group

P21
a, b, c (Å)/α, β, γ (°)

a, b, c (Å)/α, β, γ (°)

a, b, c (Å)/α, β, γ (°)

79.87, 67.22, 81.19 /
90.00, 113.95, 90.00

79.96, 67.09, 81.18/
90.00, 113.82, 90.00

79.84, 67.46, 81.36/
90.00, 113.73, 90.00

Resolution (Å)

50.00-1.85 (1.92-1.85)

74.27- 1.86 (1.96-1.86)

50.00 - 1.5 (1.55-1.50)

Rmerge (%)

2.7(22.9)

6.0 (50.9)

5.8(91.9)

No. of Reflections

238136

191427

900023

Unique Reflections

Mean I/σ(I)

66782 (6374)
43.8 (4.6)

61020 (7479)
9.7 (2.4)

125264 (12575)
34.1 (2.1)

Completeness

99.2 (95.6)

92.5 (78.4)

99.0 (100.0)

Multiplicity

3.6 (3.1)

3.1 (2.9)

7.2 (6.8)

30.53 -1.85 (1.90-

43.98 -1.86 (1.91-

27.06 - 1.50 (1.54-

Cell dimensions

Refinement
Resolution (Å)
Rwork/Rfree
R.m.s
Bond lengths
Å
Bond angles
(º)

19.7(27.1)/24.2(34.3) 20.9(32.2)/26.4(35.8) 21.7(23.9)/25.5(29.1)
0.006

0.006

0.005

1.158

1.068

1.120

M. Chain

16.9

28.2

16.7

S. Chain &

22.0

31.9

21.2

Ligands**

38.7

31.5

17.4

B-factors

Ramachandran
0.44 %
0.29 %
0.29 %
Plot Outliers
The value for the highest resolution shell is given in parenthesis. Diffraction data
collected at home-sourced X-ray generator at the wavelength of 1.5418 Å. Diffraction
data for SCAcQLALF and SCAcQLDLA were processed with MOSFLM and SCALA while
others were with HKL2000.
* Diffraction data collected at BeamlineMX1, Australian Synchrotron, at the
wavelength of 0.95 Å; **Ligands refer to the short peptides/analogues.
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Table 3.2. Effects of single-residue mutations on LM consensus peptide binding to the SC as determined by FP.
a
Peptide
IC50(µM)
Kd (µM)
∆G (298K) (kcal/mol)
∆∆G b∆∆∆GA–G
AcQLDLF
1.9
0.9
–8.3
0.00
QLDLF
63.2
29.5
–6.2
2.10
Ac0
AcELDLF
222.1
103.6
–5.5
2.85
AcNLDLF
43.6
20.3
–6.4
1.88
Q1
AcALDLF
602.6
281.2
–4.9
3.44
AcGLDLF
976.5
455.7
–4.6
3.73
0.29
AcQVDLF
60.4
28.2
–6.2
2.07
AcQADLF
78.6
36.7
–6.1
2.23
L2
AcQGDLF
36.1
16.8
–6.5
1.76
-0.46
AcQLALF
3.4
1.6
–7.9
0.37
D3
AcQLGLF
10.4
4.9
–7.3
1.03
0.66
AcQLDVF
1215.0
567.0
–4.4
3.86
AcQLDAF
246.7
115.1
–5.4
2.91
L4
AcQLDGF
1524.0
711.2
–4.3
3.99
1.08
AcQLDLL
20.96
9.8
–6.9
1.44
AcQLDLA
555.2
259.1
–4.9
3.39
F5
AcQLDLG
1067.0
497.9
–4.5
3.78
0.39
a
b
Binding energy difference compared to AcQLDLF. Difference in binding energy upon replacing alanine with glycine.

Mutation
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3.3.3 Entropy loss upon binding diminishes linear motif affinity for the E. coli SC
The alanine and glycine scans above showed that these mutations significantly
reduce binding affinity, with a higher penalty observed for glycine (except at position
L2). This can be explained by the reduced hydrophobic interactions possible with
glycine (vs alanine) and because of the higher flexibility of glycine residues. Since
glycine can adopt a greater range of backbone phi/psi angles compared to alanine there
is a greater entropic cost associated with its binding.
Molecular dynamics (MD) simulations and molecular mechanics (MM) calculations
with Poisson-Boltzmann surface area (PBSA) solvation were performed to decompose
the energy of LM peptides binding to the SC and to quantify the contribution of ligand
deformation entropy. The following equation shows how the changes in Gibbs free
energy (∆G) were decomposed:119
∆G = Gcomplex–Greceptor– Gligand
=EMM + Esolv +Edef – T∆S
=Evdw +Eelec + Epb + Ecavity +Edef– T∆S
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Table 3.3 MD simulation and MM-PBSA calculation data for peptides binding to the E.
coli SC (units in kcal/mol, details in Table 3.4).
EMM + Esolv

Edef

–T∆Sdef

–T∆S

∆G

AcQLDLF

–49.6

1.4

6.5

20.8

–27.3

AcALDLF

–40.7

3.2

4.2

21.6

–15.8

AcQADLF

–45.9

–0.1

5.5

18.3

–27.7

AcQLALF

–47.3

–0.8

–1.1

22.5

–25.6

AcQLDAF

–44.4

0.4

4.8

20.2

–23.8

AcQLDLA

–45.7

2.0

4.2

23.6

–20.1

Briefly, EMM represents the molecular mechanics (MM) interaction energy difference
upon complex formation, which comprises the van der Waals (VDW) interaction energy
(Evdw) and electrostatic interaction energy (Eelec). Esolv is the difference in solvation
energy and is comprised of electrostatic contribution to the solvation free energy (Epb)
and non-polar contribution to the solvation free energy (Ecavity). Both EMM and Esolv were
calculated for the complex using a single-trajectory approach.119 The ligand energy
difference upon binding (deformation energy, Edef) was calculated from a separate MD
simulation and MM/PBSA calculation on the free peptide alone in explicit water (EFree),
and the energy of the bound peptide (Ebound). Receptor deformation in the calculation of
EMM and Esolv was ignored for two reasons: (1) the SC undergoes minor, uniform
structural changes upon binding and (2) significant errors are possible due to
insufficient sampling of large systems in MM-PBSA calculations. Such errors cannot be
cancelled out as they can when using the single-trajectory approach. Conformational
entropy was calculated using the triple-trajectory approach with normal mode
analysis;119 the trajectories for the complex (10 ns), the receptor (10 ns) and the ligand
(50 ns) were analyzed and their entropic contributions to the Gibbs free energy (–T∆S)
are presented (Table 3.3). Ligand deformation entropy (–T∆Sdef) is also presented.
Although these calculations (Table 3.3 and Table 3.4) did not reproduce the
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experimentally determined binding free energies,1 they performed well in distinguishing
the good (i.e. AcQLDLF, AcQADLF and AcQLALF) from the poor binders (i.e.
AcALDLF, AcQLDAF and AcQLDLA) in a pattern consistent with the FP data (Table
3.2).
The VDW interactions (Evdw, Table 3.4) are proportional to ligand size, but increases
in Evdw are offset by loss of conformational entropy upon binding. Greater VDW
interactions are also offset by higher desolvation penalties. Similarly, enhanced
electrostatic interactions (Table 3.4) are offset by unfavorable desolvation energy
changes resulting in a net unfavorable contribution to ∆G. The penalized contributions
(Eelec + Epb + Ecavity, Table 3.4) were similar (~10 kcal/mol) for AcQLDLF, AcALDLF
and AcQLALF, where the latter two peptides had polar residues substituted with alanine.
This is lowered by ~5 kcal/mol for AcQADLF, AcQLDAF and AcQLDLA, where nonpolar residues L/F had been replaced by alanine.
Ligand deformation energy (Edef, Table 3.3) was similar among the peptides relative
to AcQLDLF. The peptides with reduced numbers of atoms experienced conformational
entropy costs (–T∆S, Table 3.3) similar or even higher to peptides with greater numbers
of atoms. The normal mode analysis of entropy showed that, in almost all cases, the
entropic cost of ligand deformation (–T∆Sdef, Table 3.3) accounts for a significant
portion of the unfavorable conformational entropy loss (–T∆S).
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Table 3.4 MD simulation and MM/PBSA calculation of SC/peptide complexes.*
MM calculation

SCAcQLDLF

SCAcALDLF

SCAcQADLF

SCAcQLALF

SCAcQLDAF

SCAcQLDLA

EVDW

-58.1±0.1

-50.7±0.1

-48.7±0.12

-54.4±0.1

-47.1±0.1

-50.2±0.1

Eelec

-72.3±0.8

11.1±0.9

-10.0±0.9

-30.0±0.8

-7.7±1.01

-38.8±1.7

EPB

86.0±0.7

3.9±0.7

17.6±0.8

42.2±0.7

15.2±0.9

48.2±1.6

ECAVITY

-5.2±0.01

-5.0±0.01

-4.7±0.01

-5.1±0.01

-4.8±0.01

-4.8±0.01

EMM + Esolv

-49.59±0.2

-40.7±0.3

-45.9±0.2

-47.3±0.2

-44.4±0.20

-45.7±0.3

EFREE

-215.1±0.1

-150.9±0.1

-198.5±0.1

-145.8±0.1

-198.9±0.1

-219.8±0.1

EBOUND

-213.7±0.2

-147.7±0.2

-198.6±0.2

-146.6±0.2

-198.5±0.2

-217.8±0.2

Edef

1.4

3.2

-0.06

-0.8

0.4

2.0

TS complex

2839.9±0.1

2831.3±0.1

2835.8±0.1

2832.1±0.1

2834.1±0.1

2829.3±0.1

TS receptor

2765.1±0.1

2765.1±0.1

2765.1±0.1

2765.1±0.1

2765.1±0.1

2765.1±0.1

TS free ligand

95.7±0.03

87.8±0.03

88.9±0.04

89.6±0.04

89.2±0.04

87.8±0.03

TS bound ligand

89.1±0.05

83.6±0.04

83.4±0.05

90.7±0.01

84.4±0.04

83.6±0.03

6.5

4.2

5.5

-1.1

4.8

4.2

-∆TS

20.8

21.6

18.3

22.5

20.2

23.6

∆G

-27.3

-15.8

-27.7

-25.6

-23.8

-20.1

Ligand Deformation**

Conformational Entropy

-∆TSdef

***

0.00
11.6
-0.3
1.7
3.5
7.3
∆∆G
*Errors represent standard error of mean.
**Ligand deformation is the difference between the internal energy of the ligand in the bound and free states.
***Entropy of ligand deformation is the difference between the entropy by normal mode calculation in the bound and free states.
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Table 3.5 Thermodynamic data for peptides binding to the E. coli SC as determined by
ITC (at 298K, units in kcal/mol).
∆H

–T∆S

∆G

AcQLDLF

–13.66

5.36

–8.30

Ac0

QLDLF

–6.39

0.35

–6.03

Q1

AcNLDLF

–7.40

1.83

–5.57

L2

AcQVDLF

–11.93

5.60

–6.33

AcQADLF

–13.60

7.21

–6.39

AcQGDLF

–14.66

8.05

–6.61

D3

AcQLALF

–12.18

3.73

–8.46

F5

AcQLDLL

–11.00

3.99

–7.01

Isothermal titration calorimetry (ITC) was used to further investigate the impact of
ligand deformation on entropy. Only strong binders were examined in these experiments
as ligand solubility and receptor concentration placed limitations on the measurable
binding constants. The ∆G values from the ITC measurements (Table 3.5, Figure 3.6)
were found to be consistent with the FP results (Table 3.2). Entropy values (–T∆S)
derived from the ITC measurements included both the conformational entropy and
desolvation entropy and hence are not identical to the corresponding term in the
computational studies (Table 3.3).
The greatly reduced entropic cost of binding observed when Q1 was mutated to
asparagine suggests that the bound N1-containing peptide is poorly ordered. This
correlates well with the poorly ordered peptide structure observed in the SCAcALDLF
crystal structure (Figure 3.5B). The peptide lacking the Ac0 group is probably also
disordered when bound given its low binding entropic penalty. The entropic costs of
binding for peptides with mutations at positions L2, D3and F5 were all similar to the
reference peptide, suggesting these would likely adopt similar peptide-binding poses to
that observed in the reference SCAcQLDLF structure. In the cases of D3 and F5
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replacement, it is likely that reductions in residue size and the resulting reductions in
desolvation energy produced the net reductions in entropic cost of binding when
compared to the reference AcQLDLF peptide.
Replacement of L2 with valine, alanine or glycine showed similar binding enthalpy
with increased entropic costs of binding compared with the reference peptide. This may
be explained by the higher flexibility (and hence conformational entropy) of unbound
peptides containing smaller side chains at position 2 resulting in increased entropy loss
upon binding of these peptides to the SC. This supports our hypothesis that differences
in ligand deformation accounts for a significant part of the entropy of binding. By
comparison, F5 is a terminal residue and its contribution to overall vibrational freedom
(and hence conformational entropy) would be smaller.
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A

C

B

D

Figure 3.6 Isothermal titration calorimetry data of peptides (A-I, AcQLDLF, QLDLF,
AcNLDLF, AcQVDLF, AcQADLF, AcQGDLF, AcQLALF, AcQLGLF and
AcQLDLL, respectively) binding to the E. coli SC. Curves were fitted using the model
for one-site binding.
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E

F

G

H

Figure 3.6 (continued). Isothermal titration calorimetry data of peptides (A-I,
AcQLDLF, QLDLF, AcNLDLF, AcQVDLF, AcQADLF, AcQGDLF, AcQLALF,
AcQLGLF and AcQLDLL, respectively) binding to the E. coli SC. Curves were fitted
using the model for one-site binding.
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I

Figure 3.6 (continued). Isothermal titration calorimetry data of peptides (A-I,
AcQLDLF, QLDLF, AcNLDLF, AcQVDLF, AcQADLF, AcQGDLF, AcQLALF,
AcQLGLF and AcQLDLL, respectively) binding to the E. coli SC. Curves were fitted
using the model for one-site binding.
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3.3.4 An anchor-based sequential binding model for LM recognition by the E. coli SC
The impact of A or G mutations at L4 on binding affinity, as measured by FP (Table
3.2), suggested a crucial role for this residue in the binding process: the alanine mutant
had reduced affinity due to reduced interaction, while the glycine mutant impaired
binding to a much greater extent. It is proposed that deformation entropy of the ligand
cannot fully account for the disproportionate effect of alanine to glycine substitution at
position L4 (and to a lesser extent D3) compared to other positions. This finding led us
to propose a sequential binding model whereby the L4F5 sub-motif establishes primary
contacts with the subsite I pocket, which is then followed by orientation and binding of
the flanking residues of the peptide in subsite II. According to this model, the entropic
penalty of ligand deformation for glycine mutations at the D3 or L4 positions would
disfavor subsequent binding of the Ac0Q1L2 sub-motif. This model can explain the
impact of mutations on the kinetic constants of LM association and dissociation, with
surface plasmon resonance experiments having shown that such interactions are fast-on
and fast-off,38 a feature which is commonly observed in LM binding.128 Given the rapid
kinetics, the dissociation phenomenon was considered to be amenable to steered
molecular dynamics (SMD) simulations.
The early dissociation process of the Ac0Q1L2A3L4F5mutant peptide from the SC was
chosen for the simulation. The D3 to alanine mutant was used because of its small size
and because D3 was shown to make only a minor contribution to the binding energy.
Three calculations were performed where steering forces were applied to the mass
centers of (1) the whole peptide, (2) the Ac0Q1L2 and (3) L4F5 sub-motifs (Figure 3.7).
The Boltzmann-averaged cumulative work calculated after Jacobian correction121
suggested that the L4F5 sub-motif is more likely to dissociate from the complex first as it
requires the least work (i.e. shallowest slope in the trajectory). Additionally, the
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calculations showed that a lower energy barrier lies along the L4F5 binding/dissociating
pathway in comparison with the pathway in which Ac0Q1L2 dissociates first (as
indicated by reduced cumulative work).
Binding of the dipeptides AcQL, AcLF (and their various C/N-terminal variants) to
the SC was assessed next by FP assay and X-ray crystallography to test the hypothesis
that the L4F5 sub-motif must bind/unbind first. AcQL and its analogues failed to show
any binding to the clamp by either method. In contrast, AcLF and its analogue 4MF
((S)-2-(4-methylpentanamido)-3-phenylpropanoic acid) showed weak affinity (IC50=1.1
and 4.4 mM respectively, Table 3.6) and both were shown to occupy subsite I in their
respective X-ray structures, SCAcLF and SC4MF (Figure 3.8A–C, crystallographic data in
Table 3.1 and Table 3.7). AcQL and its C-terminal variants failed to demonstrate
binding by X-ray crystallography even when AcLF was pre-bound into subsite I
(crystallographic data not shown).
The SC4MF complex structure, determined in space group (P1), showed that binding
of 4MF causes a minor perturbation of the binding pocket at S346 and H175 (Figure
3.8A) when compared with an apo-SC structure determined in the same space group
(SCP1, crystallographic data in Table 3.7). A gating residue M362 retains a “closed”
conformation (Chi2 angle –177°) in both of these structures, which blocks the
passageway between subsites I and II (Figure 3.8A).
The structure of the SCAcLF complex, determined in space group P21, showed that
binding of dipeptide AcLF to chain B of the SC (Figure 3.8B) causes no apparent
changes in the binding site, as compared with the apo-clamp structure determined in the
same space group (PDB entry 1MMI, Figure 3.8B). In both of these structures, the
M362 gating residue retains the “closed” conformation. However, when the same
dipeptide bound to chain A (Figure 3.8C) the binding features observed were similar to
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those seen with longer peptides (e.g. AcQLDLF and DNA Pol IV little finger domain,
Figure 3.8D), including movements in the side chains of M362 and S364. The binding
observed in chain B appears to be due to stabilization by a nearby symmetry-related
molecule (Figure 3.9) and may represent a pre-equilibrium state, with equilibrium
binding guided by desolvation and formation of an H-bond between the L4 amide and
G174 carbonyl groups. The gating residue M362 is unmoved in chain B (Chi2 angle –
170°) but is in a "half-open" conformation (Chi2 angle –74° and -93° for alternate
conformers) in chain A, which exposes the G174 carbonyl group as an H-bond acceptor.
The SCAcLF and SC4MF crystal structures suggest that the L4F5 sub-motif acts as an
anchor capable of binding on its own. The SC4MF, SCAcLF and SCAcQLALF complex
structures are proposed to exemplify snapshots along the pathway to binding. The
compound 4MF bound in subsite I highlights the initial contact, while AcLF makes an
additional H-bond with G174 and subsequently triggers partial opening of the M362
gate. AcQLALF occupies subsite I and subsite II with the M362 in the fully "open"
conformation (Chi2 55°, Figure 3D). The SMD simulation of AcQLALF dissociation
(Figure 3.7) demonstrated that “pulling” the anchor sub-motif (L4F5) reduces the
energetic barrier for dissociation of the rest of the peptide.
In summary, the model proposes that the binding (or unbinding) of the L4F5 anchor
sub-motif triggers subsequent binding (or unbinding) of the Ac0Q1L2 sub-motif. Acting
together, these two sub-motifs contribute most of the binding energy of the consensus
motif, as evidenced by the FP data. Since the binding of the consensus motif determines
the binding of the entire protein,42,44 the binding of the consensus motif should precede
the binding of the rest of protein. For instance, in the case of the "little finger" domain
of DNA Pol IV (PDB entry 1UUN, Figure 3.8D), the terminal residues equivalent to
the consensus motif should initiate both binding and unbinding.
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Figure 3.7 Plot of cumulative work vs distance during SMD simulated dissociation of AcQLALF from the SC. Steering forces were applied to
the three different centers of mass indicated.
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Table 3.6 Dipeptides and analogues used to probe the minimal binding motif.
Original sequence

Dipeptide/analogues

IC50 (by FP assay)

(NH2)-LF-(COOH)

N/A

Ac-LF-(COOH)
4MF

1.1 mM

O

-L4F5

O

HO

4.44 mM

N
H

AcQL-(COOH)

N/A

AcQL-(CONH2)
AcQL-(CONHCH3)

N/A
N/A

O

H
N

N
H

O

N/A

Ac0Q1L2-

NH2

O
O

H
N

N
H

O

N/A
O

NH2
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Table 3.7. Data collection and refinement statistics of E. coli SC in its native form
(space group P1) and in complex with 4MF ((S)-2-(4-methylpentanamido)-3phenylpropanoic acid).
Name

SCP1*

SC4MF**

PDB Code

4K3S

4K3K

Data collection
Space group

P1
a, b, c (Å)/α, β, γ (°)

a, b, c (Å)/α, β, γ (°)

Cell dimensions
40.98, 64.97, 71.93/
82.46, 84.04

73.81,

41.02, 64.69, 71.78 /
83.22, 85.18

74.66,

Resolution (Å)

68.68-1.75 (1.84-1.75)

50.00-1.85 (1.92-1.85)

Rmerge (%)

6.7(45.6)

2.9(12.9)

No. of Reflections

246547

219297

Unique Reflections

67726 (9775)

56309 (4695)

Mean I/σ(I)

10.7 (2.4)

44.4 (9.4)

Completeness (%)

95.3 (93.8)

93.2 (78.4)

Multiplicity

3.6 (3.5)

3.9 (3.6)

Resolution (Å)

28.24 -1.75 (1.80-1.75)

34.95 -1.85 (1.90-1.85)

Rwork/Rfree (%)

19.5(29.0)/22.9(32.8)

19.4(22.7)/22.9(27.5)

Bond lengths (Å)

0.007

0.005

Bond angles (º)

1.247

1.063

M. Chain

22.8

17.2

S. Chain & Water

26.9

20.5

Ligands***

N/A

20.0

Ramachandran Plot
Outliers

0.29 %

0.28 %

Refinement

R.m.s deviations

B-factors

The value for the highest resolution shell is given in parentheses.
Diffraction data for SCP1 were processed with MOSFLM and SCALA while SC4MF were with
HKL2000.
* Diffraction data collected at BeamlineMX1, Australian Synchrotron, at wavelength 0.95 Å;
**Diffraction data collected at home-sourced X-ray generator at the wavelength of 1.5418 Å;
***Ligands refer to the short peptides/analogues.
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D

Figure 3.8. Crystal structures of SC4MF (A), and SCAcLF chain B (B) and SCAcLF chain A
(C). SC residues are presented in white with non-carbon atoms CPK-colored. Structures
of the equivalent native SC structures with equivalent crystal packing are superimposed
and shown in yellow (SCP1 onto SC4MF, chain B and A of PDB entry 1MMI onto SCAcLF
chain B and A, respectively). The peptide atoms are CPK-colored. Dashed lines in red
represent H-bonds. Electron density maps (mFo–DFc) contoured at 3σ are shown in
green wire-basket form. (D) The crystal structure of the SC/pol IV little finger domain
(PDB entry 1UNN) is shown superimposed onto SCAcQLALF. The DNA Pol IV little
finger domain is shown in pink. The enlarged view of the binding pocket in the
SCAcQLALF structure shows the SC pocket (white), the AcQLALF peptide (grey). Noncarbon atoms are CPK-colored. Dashed lines in red represent H-bonds. A bridging
water molecule (W0) is shown as a red sphere.
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Figure 3.9. The region around the AcLF dipeptide bound to SC chain B in the SCAcLF
complex (P1 space group). A symmetry-related molecule (cyan) is in contact with the
AcLF dipeptide. The SC is present in white/cyan with non-carbon atoms CPK-colored.
The AcLF atoms are CPK-colored. The dashed line represents an H-bond. Electron
density maps (mFo–DFc) contoured at 3 σ are shown in green wire-basket form.
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3.3.5 Almost-buried polar atoms (ABPAs) present a kinetic barrier
The mutational analysis of consensus peptide binding suggested equal importance for
the L4F5 and Ac0Q1 motifs to affinity, with the L4F5 sub-motif functioning as an anchor
to initiate binding. Initially the "closed" conformation of M362 was considered to act as
a gate blocking binding at subsite II. However, MD simulations of the native SC
monomer showed that the M362 Chi2 angles corresponding to the open/closed
conformations are equally populated in the trajectory (Figure 3.10), suggesting that the
conformation of M362 is probably not determining the order of binding.
A kinetic barrier, caused by differences in the nature of desolvation and resolvation
of subsites I and II, is proposed to be responsible for the L4F5 sub-motif to act as the
anchor sub-motif. Subsite I consists mostly of hydrophobic residues which contact the
side chains of L4F5 (Figure 3.13A). In contrast, subsite II makes multiple H-bonds with
the Ac0Q1L2 sub-motif (Figure 3.13B), including some mediated by the bridging water
(W0). The trajectory of a 5 ns native SC simulation, which included all crystallographic
water molecules, showed that W0 remained bound (Figure 3.11) and was tightly
restrained by H-bonds toM362O and N320N (Figure 3.12). It was therefore concluded
that W0 is a structural water molecule in the SC.
A recent study showed that H-bond interactions between the protein and ligands that
are shielded from bulk solvent contribute to slow binding/unbinding kinetics.118 This
was explained by the desolvation and resolvation of "almost-buried polar atoms"
(ABPAs) upon ligand binding/unbinding, which involves a transition state that is
energetically

unfavorable

because

it

occurs

asynchronously

with

dehydration/rehydration.118 ABPA refers to atoms with <10 Å2 solvent accessible
surface area (SASA) located within a concave site where the ∆SASA is < 0 (change of
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SASA with increased probe radius). For the E. coli SC, W0 and M362O are ABPA
atoms according to this definition while all other polar atoms making H-bonds in both
subsites I and II are non-ABPAs (Table 3.8).
To determine the role of W0 and M362O as ABPAs along the proposed dissociation
pathway, SMD simulations of a model AcQL dipeptide dissociating from subsite II
were performed using initial coordinates from the SCAcQLALF complex structure. For
comparison, a SMD simulation was carried out for dissociation of AcLF from subsite I,
using coordinates from the SCAcLF complex as the starting structure. The AcLF
dipeptide makes one H-bond with a G174O, a non-ABPA. Jacobian corrections were
applied in the cumulative work calculations.121
The cumulative work plot for AcLF dissociation is uniformly ascending showing
only one energetic minimum (Figure 3.13C). As a non-ABAP, the G174O in subsite I
is solvent accessible even when AcLF is bound (Figure 3.13G). The breaking of the Hbond with the dissociating AcLF (Figure 3.13E) is offset by increasing contacts with
bulk solvent (Figure 3.13G), thus no kinetic barrier is observed in the case of AcLF
dissociation (Figure 3.13C).
The cumulative work of steered dissociation of the model AcQL began with a steep
ascending curve which quickly flattened (Figure 3.13D). This represents the peak of an
energy barrier where the system could dissociate or re-associate. Dissociation was
accompanied by the breakage of the H-bond between the W0 and the Q1 side chain
(Figure 3.13F) and reformation of H-bonds with the solvent (i.e. first layer resolvation)
(Figure 3.13H). Breakage of the H-bond between M362O and the Q1 side chain
preceded breakage of the W0 to Q1 H-bond (Figure 3.13F), while resolvation of M362O
was insignificant (Figure 3.13H). At a distance of 1.5 Å, abrupt dissociation of the W0
to Q1 H-bond occurs, leading to greater movement of the Q1 side chain (Figure 3.13F)
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and formation of the first solvent layer in subsite II. Prior to this event, W0 is completely
shielded from bulk solvent. Thus, there was a transient state (distance <1.5 Å) where the
system increases in energy as the H-bond with W0 is broken with no compensatory
formation of H-bonds with the first solvation layer.
It is proposed that the desolvation and resolvation of the structural water W1 as an
ABPA represents the kinetic barrier on the pathway of dissociation. The same barrier
must be present in association since the ligand is barred by the first solvent layer that
forms H-bonds with the W0 shielded from bulk solvent. Such a kinetic barrier may have
a larger impact on the association rate constant than on the dissociation rate constant of
AcQL and its variants, and therefore reduced the affinity. However, in case of the
AcQLALF binding (Figure 3.7), the first solvent layer should be disrupted by the
presence of Ac0Q1L2 sub-motif near subsite II as a result of L4F5 binding to subsite I,
and thus the kinetic barrier presents greater resistance to dissociation than association.
This explains the energetic contribution of the Ac0Q1L2 sub-motif observed earlier
(Table 3.2).
Conversely, binding of AcLF to the SC is not opposed by this barrier as it is not
present in subsite I. A similar kinetic barrier was observed in the work plot for the SMD
simulation of the SCAcQLALF complex structure steered at the Ac0Q1L2 sub-motif
(Figure 3.7).
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Figure 3.10 M362Chi2 angle during a 10 ns simulation of the E. coli SC. Green arrows
indicate the "closed" conformation with Chi2 angle distributed around -180°; Red arrow
indicates the "open" conformation with Chi2 angle around 70°.

Figure 3.11 RMSF (Root Mean Square Fluctuation) plot of crystallographic waters
during a 5 ns MD simulation of the native SC. Red square represents the structural
water W0.
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Figure 3.12 Radial distribution function of the distances between W0 and
M362O/N320N, respectively. Data extracted from a 5 ns MD simulation of a native SC.

Table 3.8 Solvation profile of the hydrogen bonding polar atoms in subsite I and II.
∆SASA
∆SASA, %
(probe radius +0.1 Å)

SASA
(Probe radius 1.4 Å)

SASA
(Probe radius 1.5 Å)

W0

2.7

2.3

-0.4

-15.6

M362O

2.1

1.7

-0.4

-20.3

P363O

19.2

19.1

-0.1

-0.6

R365N

9.7

9.5

-0.2

-2.1

G174O

28.1

28.3

0.2

0.6
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Figure 3.13 (A, B) Model structures for SMD simulation of AcLF and AcQL
dissociation from subsites I and II, respectively. The dipeptides are colored grey and the
binding pockets white. Non-carbon atoms are CPK-colored. Dashed lines represent Hbonds. A bridging water (W0) is shown as a red sphere. (C, D) Boltzmann-averaged
cumulative work of the dipeptides pulled for 5 Å from the mass center of the pockets.
(E, F) Distances of H-bond pair atoms presented as a Boltzmann-average of 20
simulation trajectories. (G, H) Number of water contacts (<3.4 Å) Boltzmann-averaged
with 20 simulation trajectories.
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3.4 Conclusion
The E. coli SC has several binding partners,25 all interacting via a surface binding
pocket through LMs with conserved residues. Such modularity is made possible with
specific LM-SC interaction pairs in subsites I and II. This study has identified two
critical subsite-specific interactions: (1) the non-polar contacts of the L4F5 sub-motif
with subsite I, and (2) the H-bond network of the Q1 residue with subsite II mediated by
a structurally conserved water molecule. In the proposed binding model, the L4F5 submotif establishes primary contact with subsite I, and that this interaction should be
entropically favourable due to desolvation of the hydrophobic L4F5 sub-motif and
binding site. Anchoring of the L4F5 sub-motif assists the Q1 side chain in overcoming
the kinetic barrier caused by slow formation of H-bonds with the conserved water as an
ABPA of subsite II. The H-bond network formed upon positioning of Q1 in subsite II
stabilizes the complex as the kinetic barrier similarly opposes association and
dissociation. Dissociation occurs in the same order, with the L4F5 sub-motif dissociating
first.
This sequential binding model with the L4F5 sub-motif acting as an anchor driving
both association and dissociation explains several biophysical observations, such as the
impaired binding observed for alanine and glycine mutants at positions L4 and D3
(glycine mutants pay a higher entropic penalty in ligand deformation, thus making the
Ac0Q1L2 sub-motif less likely to bind). Another example is the electron density of the
peptide in the SCAcALDLF complex, where the Ac0A1L2- sub-motif was absent while the
L4F5 anchor still showed clear electron density. A third example comes from the fact
that all peptides are fast binders because the kinetic barriers are absent or reduced
following initial association of the L4F5 anchor.
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Understanding the structural and thermodynamic basis for ligand recognition by the
E. coli SC could inform design strategies for small-molecule inhibitors as probes or
drugs. The sequential binding mechanism may be an important consideration for smallmolecule inhibition design if the critical interactions are to be reproduced.
Our observations of LM binding to the SC may be broadly applicable to the many
other examples of protein-LM recognition. As a general principle, the entropic penalty
associated with reduction of LM flexibility on receptor binding could be an important
factor that limits affinity. This principle may explain the commonly observed
micromolar affinity associated with LM recognition. The flexibility of LMs is universal
and since flexibility is a structural prerequisite for sequential binding, LMs can use this
strategy for finding their optimal binding poses. The generality of sequential binding
with LMs is supported by the prevalence of hydrophobic residues (leucine and/or
phenylalanine)96,106,112,129 which could serve as the anchor points with their lower
desolvation penalties driving binding in hydrophobic pockets.
To date, inhibition of LM recognition for therapeutic purposes has yielded few
successes. Despite the similarities, LM recognition may differ in the composition of the
anchor motif (e.g. phosphoserine/threonine-containing anchor motif recognized by
SH2/WW domains,130 PxxP binding to SH3 domain131) and potential structural
transformation (folding-coupled binding in the case of P53 binding to MDM2).132 These
factors complicate any effort to completely elucidate the binding process. The LM
recognition by the E. coli SC is a relatively simple case where the binding has no
allosteric consequences, allowing the effect of the sub-motifs to be partitioned. The
sequential binding model with differential solvation as a key driver revealed here may
also apply to evolutionarily related and/or biochemically similar systems, such as the
PCNA-mediated interactions in eukaryotic DNA replication via recognition of a -
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Qxx[I/L]xxFF motif.133 Taking into account those structural and kinetic factors will
assist drug design efforts targeting these systems.
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Chapter 4
Fragment screening
with X-ray crystallography
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4.1 Introduction
X-ray crystallography was used as the primary technique in obtaining fragment hits
against the SC. The E. coli SC gives crystals that are particularly robust and amenable
to compound soaking as demonstrated in previous work regarding various peptidic
ligands binding to the SC (see Chapter 3). The SC crystals have around 50% solvent
content and therefore can be regarded as a highly concentrated protein at near molar
level. Such high concentrations are favourable in identifying weak binders. Similarly,
the fragment compounds can be used at high concentration (5 mM), which is the level
of the expected binding affinity (Kd) of those fragments. High concentrations of both the
receptor (the SC) and the ligands (fragment compounds) ensure the detection of weak
binding affinity at the millimolar level. These interactions are barely detectable using
solution-based assays owing to limited receptor concentration (usually at the
micromolar level).
4.2 Materials and Methods
4.2.1 Fragment cocktails
The First-Pass Screen library from Zenobia Therapeutics was chosen as a fragment
library containing 352 fragment compounds in powder form. Their plate locations and
IDs are shown in Appendix Table 1–4. These fragments were dissolved and diluted to
the final concentration of 5 mM before screening. DMSO (50 µL) was added to each
well of a 96-well plate to yield a 200 mM stock solution. Cocktails were prepared by
mixing equal amounts of the 4 fragments: e.g. the first 4 fragments in a column (rows A,
B, C and D) as one cocktail and the last 4 fragments (rows E, F, G and H) as another
cocktail. A total of 88 cocktails were prepared and aliquoted into a separate plate (the
cocktail plate). The concentration of each fragment in the cocktail was 50 mM.
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4.2.2 Fragment compound soaking
Crystals were grown as described in Chapter 2. Cocktails were added to the
reservoir buffer of crystallization to yield a 10% (v/v) DMSO concentration equivalent
to 5 mM concentration of each fragment compound. Soaking was carried out by moving
crystals to reservoir buffer containing cocktail fragments. The SC crystals did not
deteriorate significantly during the overnight soaks. One crystal experienced cracking or
re-dissolved in the reservoir buffer.
Additional cryo-protection agents were not needed since > 20% (v/v) PEG 400 was
present in the reservoir buffer and that alone was sufficient.
4.2.3 Crystal mounting, X-ray data collection, data processing and structure solution
The general methods used in data collection at the Australian Synchrotron were
described in Chapter 2. Diffraction images were collected at 100 K on beamline MX1.
Crystals were rotated through 1° per frame, with 360 or 720 sequential frames collected
per crystal. Exposure time was 0.4 to 0.8 second per frame. In most cases the crystal
diffracted to resolutions of 3.0 Å or higher. Diffraction data sets were collected for
crystals soaked with cocktails. Due to limited beam time at the Australian Synchrotron,
3 X-ray data sets were collected using the in-house X-ray source (see Chapter 2).
Diffractions images were reduced and crystal structures were determined as
described in Chapter 2. Fragments bound with the SC were interpreted based on the
electron density map and composition of the cocktail soaked into the crystal. The
cocktails generally contain fragments of different geometry which aided the
interpretation of the electron density and to decide which fragment to be modelled into
the map. Individual validation of the fragment hits using an additional round of X-ray
crystallography was not carried out due limited resources.
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4.3 Results and Discussion
4.3.1 Model building of the SC crystal structure and the fragment ligand
Crystal structures were obtained for 87 out of 88 fragment soaks. One soak failed due
to crystal disintegration. Crystals belonged to either the triclinic P1 or monoclinic P21
space groups, which however could not be distinguished from examination under
microscope). In both cases, there is one SC dimer per asymmetric unit comprised of two
monomers. The SC structure was solved with molecular replacement using PDB
deposition 1MMI36 (an apo-SC structure of space group P21) removed of all non-protein
residues as the starting model. The binding pockets of both monomers are located
adjacent to crystal contacts (Table 4.1). The electron densities of all structures were
examined with particular emphasis on subsite I and II regions of each monomer. In
several structures, electron density peaks not found in subsites I or II were interpreted as
PEG chains of various length, calcium ions, chloride ions, or water molecules.
Fragment compounds totalling 18 in number (Table 4.1 and Table 4.2) were
identified corresponding to (> 3σ) positive density peaks in the mFo − DFc maps in
subsite I of Chain A and/or Chain B in crystals of both P1 and P21 space groups. Those
fragment hits were distinguished from the cocktails of fragments used based on the
electron density map and its geometry. The chance of two fragments bound to the same
site was considered unlikely due to the low hit rate. The fragment compounds were built
into the electron density map using geometric restraints prepared using Monomer
Library sketcher or PRODRG as described in Chapter 2. In case of ligands with poor
electron density, occupancies were adjusted accordingly. These complex crystal
structures are denoted as SCZTXXXX (SC for SC and ZTXXXX for the ID of the fragment
compound, i.e. ZT0008) and their crystallographic data are shown in Table 4.3.
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The corresponding fragments (Table 4.2) were built into the density and refined.
Only subsite I was observed to bind fragments. In no cases was subsite II observed to
bind any fragment compounds, although it appeared to be solvent accessible in most
cases (Table 4.1).
Compared with each other, subsite I in Chain A and Chain B have different local
chemical environments due to different crystal packing (Table 4.1). This results in
interference in the fragment binding at the subsite I of Chain B of P1-crystals. Detailed
descriptions are given in Table 4.1.
4.3.2 Pseudo-hits identified in the subsite I of Chain B of crystals of P1 space group
Seven fragment compounds (ZT0784, ZT0273, ZT0694, ZT0789, ZT0773, ZT0860
and ZT0817) were observed to bind to subsite I of chain B in P1-crystals only (Table
4.2). One fragment compound (ZT0007, Table 4.2) was found to bind to subsite I in
both chain A and chain B of crystals belonging to space group P1. Its electron density at
chain A was very poor (detailed in section 4.3.3.4) in comparison to the binding at
Chain B. Of these seven fragment compounds bound in subsite I of Chain B (but not
Chain A), interaction with the residues of a symmetry-related molecule was observed.
No binding in subsite I of Chain A was observed, and no symmetry-related molecule
equivalent to that observed near subsite I of Chain B was present. These compounds
were considered to be pseudo-hits since the interaction appears only to occur where
crystallographic interactions are present. Their crystal structures will not be discussed
further. Compound ZT0007, which also binds to the subsite I of Chain A, was
considered a hit (Table 4.2).
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4.3.2 Fragment hits
4.3.2.1 ZT0602
The fragment hit ZT0602 (3,4-difluorobenzamide), was found to bind to subsite I of
Chain A of a crystal belonging to the P1 space group (Figure 4.1) but not Chain B,
likely due to the presence of the crystal contact in Chain B. No apparent changes in the
protein were found compared with the native structure. An alternative side chain
conformation of S346 was observed, possibly as a result of the partial occupancy of the
ZT0602. This ligand has relatively poor electron density to one side of the fragment ring,
likely due to thermal fluctuations. The fluorine atom of the ligand is buried in a
spherical pocket comprising amide backbones and side chains of hydrophobic residues
V360 and M362. This pocket seems to favour the binding of halogen atoms bonded to
phenyl rings due to its complementary shape. This region accommodates the leucine
side chain of peptide ligands previously discussed (see Chapter 3.3.2).
4.3.2.2 ZT0250
The fragment hit ZT0250 (5-chloroindoline-2,3-dione), was found to bind to subsite I
of Chain A of a crystal belonging to the P1 space group (Figure 4.2). No apparent
differences in the protein were found compared with the native structure. An alternative
side chain conformation of S346 was observed, probably as a result of the partial
occupancy of ZT0250. This fragment has prominent electron density corresponding to
the chlorine atom on the phenyl ring in comparison with other groups. The chlorine
group is found buried in the spherical pocket in a manner similar to the halide group of
ZT0602 (Figure 4.1). It could be a result of the larger atomic radius of a chlorine atom
compared to carbon atom, and thus the stronger electron density. It could also partly due
to that the binding at the spherical pocket is thermodynamically more stable than the
binding to the rest of the subsite I.
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4.3.2.3 ZT0082
The fragment hit ZT0082 (5-chloro-1H-benzo[d]imidazole), was found to bind to
subsite I of Chain A of a crystal belonging to the P1 space group (Figure 4.3). No
disruption of the protein was found compared to the native structure. ZT0082 has
weaker electron density compared with other fragments, making it a less reliable hit.
This suggests lower ligand occupancy and thus poorer binding affinity.
4.3.2.4 ZT0007
The fragment hit ZT0007 (4-bromobenzamide), was found to bind to subsite I in
both Chain A and Chain B of a triclinic crystal. Its binding at Chain B appears to be due
to a symmetry-related molecule. Its binding to Chain A (Figure 4.4) appears more
likely to reflect the binding in solution as there are no nearby crystal contacts. No
apparent disruption of the protein was found compared with the native structure. An
alternative side chain conformation of S346 was found, possibly as a result of the partial
occupancy of ZT0007. This fragment has prominent electron density corresponding to
the bromine atom on the phenyl ring, while the rest of the compound had poorer density
apparently due to low occupancy. Therefore the binding pose of ZT0007 is not
convincing since the poor electron density does not support a clear orientation of the
ring.
4.3.2.5 ZT0642
The fragment hit ZT0642 (3-iodobenzoic acid), was found to bind to the subsite I of
Chain B of a crystal belonging to the P21 space group (Figure 4.5). No apparent
disruption of the protein was found compared to the native P21 structure, except for the
side chain of M362. The shift in the M362 side chain is likely due to the large size of
the iodine atom. ZT0642 has prominent electron density for the iodine atom on the
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phenyl ring but not for the rest of the compound. Thus the ambiguous placement of the
phenyl ring casts doubt on the overall binding pose of the ligand.
4.3.2.6 ZT0447
The fragment hit ZT0447 (6-nitro-1H-indazole), was found to bind to subsite I of
Chain A of a triclinic crystal (Figure 4.6). No apparent changes in protein structure
were found comparing to the native P1 crystal structure. ZT0447 has excellent electron
density that allowed unambiguous interpretation of the binding pose. ZT0447 does not
have any halogen-containing moiety occupying the hydrophobic and spherical pocket
but instead has a nitro-group forming H-bonds with both the side chain of S346 and a
crystallographic water molecule.
4.3.2.7 ZT0445
The fragment hit ZT0445 (5-nitro-1H-indole), was found to bind to the subsite I of
Chain A of a crystal belonging to the P1 space group (Figure 4.7). No apparent
disruption of the SC was found compared to the native structure. ZT0445 has very good
electron density allowing unambiguous assignment of the binding pose, which is the
same as in the case of ZT0447. Similar to ZT0447, ZT0445 does not have any halogencontaining moiety occupying the spherical pocket but instead has a nitro group in Hbonding distance of both the side chain of S346 and a crystallographic water molecule.
4.3.2.8 ZT0834
The fragment hit ZT0834 (1-(4-nitrophenyl)piperazine), was found to bind to the
subsite I of Chain A of a SC crystal belonging to the P1 space group (Figure 4.8). No
apparent changes in the binding site due to fragment binding were observed. ZT0834
has poor electron density, and neither the phenyl ring nor the piperazine ring could be
modelled into the electron density map with confidence. However, the overall electron
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density does suggest its binding, particularly the nitro group which is involved in an Hbond with the side chain of S346. The geometry of ZT0834 adopts an “S” shape
complementary to the shape of subsite I. This was not observed in the previous
fragment-bound structures: the other fragment compounds are smaller and only occupy
about a half of the subsite and have no interactions with P242 or R152. However,
although the ZT0834 indicate the possibility of fragment growth to occupy all of subsite
I, it is not a good example owing to the poor electron density and thus apparent low
occupancy compared with other hits.
4.3.2.9 ZT0428
The fragment hit ZT0428 (4-methyl-5-nitropyridin-2-amine), was found to bind to
the subsite I of Chain A of a triclinic crystal (Figure 4.9). No apparent disruption of the
protein structure was observed in comparison to the native structure. ZT0445 has good
electron density for the nitro group but not for the rest of the compound. The nitro group
is involved in an H-bond with the side chain of S346, similar to the binding of both
ZT0447 and ZT0445.
4.3.2.10 ZT0835
The fragment hit ZT0835 (1-(4-(4-hydroxyphenyl)piperazin-1-yl)ethanone), was
found to bind to the subsite I of Chain A of a crystal belonging to the P1 space group
(Figure 4.10). No changes in protein structure were observed due to fragment binding.
ZT0445 has poor electron density overall. However, the ligand was placed in density in
a similar fashion to the piperazine scaffold as ZT0834. It also shares a binding pose
similar to ZT0834 with an H-bond observed between the phenol group and the S346
side chain.
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4.3.3 Summary of the fragment hits.
All fragment hits were found to bind in subsite I. Several of them had halogen atoms
buried in a pocket consisting of the side chains of V360, Val361, Met 362 and S346.
Those fragments without this interaction had nitro- or phenol-groups forming hydrogen
bonds with the side chain of S346. The binding of the fragments had no observable
effect on the overall shape of the protein structure. With the exception of residues S346
and M362, no side chain conformations were observed to change. The binding of
halogen-containing fragments appeared to induce a shift in the S346 side chain, but the
effect was ambiguous due to the limited occupancy of the ligands. One fragment,
ZT0642 (Table 4.2, Figure 4.5) contains an iodine atom that bound close to M362 and
appears to be responsible for the observed shift in the side chain conformation.
Movements in S364 and M362 were previously observed in crystal structures of SCpeptide complexes (see Chapter 3).
4.3.4 Affinity estimation based on crystallographic occupancy determined with relative
temperature factors
4.3.4.1 Binding affinity estimation based on crystallographic occupancy
The fragment compounds screened using X-ray crystallography have an average
molecular weight around 150 Dalton, approximately 4 times smaller than pentameric
peptides (see Chapter 3). The small size and the limited number of possible
interactions impose a limit on the affinity of the fragment compounds. The consensus
motif of a pentameric peptide generally has micromolar Kd affinity, equivalent to a
Gibbs free energy of binding of around -8 kcal/mol. A fragment compound that are
about one quarter of the size should have proportionally smaller Gibbs energy of
binding (in the order of -2 kcal/mol), placing their Kd values in the millimolar range.
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Binding affinities in the millimolar range cannot be accurately measured with
fluorescence polarization assays (or indeed most solution-based assays) due to the low
receptor (SC) concentrations and limited ligand solubility at the concentration range
required for binding assays. The poor electron density observed for most fragment
compounds in the crystal structures support their low affinity and therefore the low
ligand occupancy (this could be attributed to incomplete soaking but unlikely). Ligand
occupancy can be estimated using the relative B-factors of ligand and receptor atoms
and can be used to estimate the dissociation constant (Kd) in the crystal.134 The
temperature factor of T172Oγ atom was used as a reference to represent the
thermodynamic movement of molecules in the region closest to the bound ligand. The
temperature factor of the ligand atom closest to the T172Oγ was compared to that of
T172Oγ, and the ratio can be deemed as the crystallographic occupancy. The Kd can be
approximated taking into account the fragment compound concentration used in soaking
([L]), which was 5 mM in all cases:134
Occupancy = (Ligand B-factor)/( T172Oγ B-factor)
Kd = ((1/Occupancy)-1) x [L]
The resulting Kd values were used to calculate the Gibbs free energy of binding and
ligand efficiency (See Table 4.4).
4.3.4.2 Lipoligand efficiency (LLEAT)
Ligand efficiency (LE) is generally used to show the efficiency of ligand-binding in
terms of binding affinity and ligand size. A limitation of LE is the failure to account for
the solvation/desolvation profiles of the ligand. For example, a potent hydrophobic
ligand may not be soluble enough to have a favourable pharmacological profile. The
solvation and desolvation profiles of a compound (i.e., the LogD value under
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physiological conditions) is critical to a compound’s pharmacological potential.
Lipoligand efficiency (LLEAT) was used as an indicator of the suitability of the ligands
(or compounds) which takes the LogD values (at pH 7.2) of the compounds into account.
LLEAT was introduced by Mortenson et al. as an advanced indicator of compound
potency and potential to be developed into drug-like molecules.135 Its calculation
includes the compound’s solubility as a variable.
The equations used to determine the LLEAT and related terms in Table 4.4 are
detailed below:
LE = –∆G/HAC
= –RTln(Kd)/HAC
∆G* = ∆G – ∆Glipo
=RTln(Kd) + RTLogD
LLEAT = 0.11 - ∆G*/HAC
Where LE is the Ligand efficiency, HAC is the heavy atom counts, LogD is the
Partition coefficient at pH 7.2 and LLEAT is the Lipoligand efficiency. Ligands with
values around 0.3 suggest balanced binding affinity, molecular weight and solubility.
4.3.4.3 Estimated affinity and LLEAT for the fragment hits
The temperature factors for ligands (Ligand B-factor, Table 4.4) are generally higher
than the temperature factors for the receptor residue (T172Oγ B-factor, Table 4.4). This
gave ligand occupancies mostly less than 50% (Occupancy, Table 4.4). Since the
concentration of the fragment compounds used for soaking was 5 mM, the affinity in
crystallo (Kd, Table 4.4) and Gibbs free energy (ΔG, Table 4.4) can be calculated. The
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numbers of the non-hydrogen heavy atom were presented (HAC, Table 4.4) and then
the ligand efficiency values followed (LE, Table 4.4).
The fragment hits generally have estimated affinities in the range 5 to 20 mM. These
estimates are only approximate: the tightest binding fragments cannot be distinguished
among the ensemble. Since the differences of the affinity values of the fragment hits
were not in the order of magnitudes, it does not contribute significantly to the
calculation of LLEAT values, which are more reliant on the solvation and desolvation
profiles of a compound. The LLEAT values were used to aid the decision of which
fragments to select for further development. However, the results (LLEAT, Table 4.4)
found that most of the fragment lay within the range of 0.2 to 0.4. The LLEAT metric
puts significant weight on the desolvation energy. LLEAT values for fragments can be
misleading since modification of functional groups or the scaffold can significantly alter
the LogD values (LogD, Table 4.4) in comparison to the effects of modification on
larger compounds. Therefore, those fragments with LLEAT values between 0.2-0.4 are
considered worthy of further consideration.
4.3.5 Directions for fragment growth
4.3.5.1 The preference of halogenated aromatic rings
Many fragment hits had halogenated aromatic rings. The halogen atoms of the
fragments were consistently found to occupy an approximately spherical pocket
comprised of the side chains of hydrophobic residues. In these complex crystal
structures, the halogen atoms are the most prominent, as demonstrated by the clear
electron density, suggesting thermodynamically stabilized interactions of the halogen
atoms with the adjacent residues and/or the higher number of electrons possessed by
chlorine, bromine and iodine atoms. Halogenated aromatic rings were therefore
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postulated to be desirable moieties to be preserved in further development of the
fragment hits. As to which halogen might be used in further design, iodine- and
bromine-containing fragment hits (ZT0007 and ZT0642, Figure 4.4-4.5) that had
relatively poor electron density were precluded. The LLEAT values for the two fragment
compounds are not within the acceptable range (0.2 - 0.4). Further design efforts
focused mainly on fluoro and chloro substitutions on aromatic rings.
4.3.5.2 H-bonds with S346 are critical to the affinity
Several fragment hits featured nitro-groups on aromatic rings. Despite having no
halogen atoms to occupy the spherical pocket, good electron was density for ZT0047
and ZT0045 was observed in their respective complex crystal structures with the SC
(Figures 4.6-4.7). These fragment compounds have hetero rings of similar geometry to
ZT0082 (Figure 4.3) but much better electron density and possibly higher binding
affinity (Table 4.4). The major difference is the presence of H-bonds with the side chain
of S346: ZT0047 and ZT0045 have multiple H-bonds including one with S346 while
ZT0082 forms no H-bonds. The H-bond with S346 is a favourable interaction that could
be reproduced in candidate inhibitors. Halogenated rings could be combined with
functional groups capable of making H-bonds with S346 (e.g., carboxylic acid, phenol,
or carbonyl groups). A cursory examination of the binding poses of fragment hits
containing halogen atoms or nitro groups indicate that these two substitutions should be
able to form favourable interactions with the substituents in the ortho position.
4.3.5.3 Fragment growth to occupy the entire subsite I
All fragment hits occupied subsite I, having contacts with residues S346, V360, L177,
V247, M362 and T172. Two other fragment hits (ZT0834 and ZT0835) extended
toward a shallower region in the vicinity of P242 and R152. These two residues are
responsible for the slight bend in the subsite I cavity, mostly because the side chain of
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P242 protrudes into the binding site. In the cases of the binding of both ZT0834 and
ZT0835 (Figure 4.8-4.9), their piperazine rings have the flexibility to prevent clashes
with P242. The guanidine group of the R152 side chain may be another driving force of
the positioning of ZT0834 and ZT0835 due to the formation of H-bonds with the aceto
group of ZT0835, and the presence of a bridging water molecule in between the R152
and the piperazine amine of ZT0834. Although these two fragment hits had poor
electron density, they are informative in guiding the design of an aromatic scaffold with
an extended flexible component.
4.3.5.4 M362 as a gating residue may allow extension of developed fragments to subsite
II
Residue M362 was previously identified as a gate controlling the channel from
subsite I to subsite II. M362 had no significant change in conformation in most crystal
structures of the fragment hits bound with the SC. The only exception was ZT0642
(Figure 4.5), which triggered the opening of the gating residue M362 in a similar
fashion to what was observed with the binding of AcLF dipeptide (see Chapter 3). The
AcLF dipeptide has an acetyl group occupying the channel between subsite I and
subsite II, but ZT0642 does not have such substructure. A plausible explanation for the
perturbation of M362 is that the large radius of the iodine atom, which may impose
steric hindrance upon the M362 side chain.
4.4 Conclusion
A total of 352 fragment compounds were screened with X-ray crystallography and,
despite 6 questionable hits that appeared to be a result of crystal packing, 11 hits were
identified. Among them 4 (ZT0602, ZT0250, ZT0447 and ZT0445) have electron
density in the 2mFo-DFc map that unambiguously support the binding pose of the
fragments compounds while the other 7 had weaker electron density.
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Analysis of protein-fragment interactions revealed binding of halogen groups at a
pocket comprised of hydrophobic residues V360, L177, V247 and M362. A halogenbond with the side chain of S346 was found to be important to the binding affinity.
Most fragment hits occupy only the deep region of subsite I while binding at the
shallow region of the subsite I was observed two larger fragment hits (ZT0834 and
ZT0835).
The finding that most fragment hits bind to the deep region of subsite I and no hits in
subsite II is consistent with the study of LM recognition by the E. coli SC (Chapter 3).
The sequential binding model proposed for LM recognition suggests the subsite I as the
“anchor site” which shall be preferentially occupied compared with subsite II. All
fragment hits have aromatic ring(s) with or without halogen substituents bound at the
deep region, where the leucine residue of the LF sub-motif of peptidic ligands is
positioned when bound. This is corroborative evidence that the deep region of subsite I
is the hotspot of molecular recognition by the SC. Additionally, ZT0834 and ZT0835
also occupy the shallow region where the phenylalanine residue of the LF sub-motif is
positioned, which may have positive contributions to the binding affinity.
Ligand occupancies of the fragments were estimated based on the temperature
factors of a ligand atom relative to the closest SC atom. In turn, the occupancy was used
to estimate the affinity in crystallo. The calculated Kd values suggested millimolar
affinity for all fragment hits and further analysis of their lipo-ligand efficiency (LLEAT,
Table 4.4) provided aid in the decision as to which fragment were entered into the next
round of development. The fragment hits with LLEAT values between 0.2-0.4 were
deemed most promising with favourable desolvation profiles and will be highlighted in
future hit-to-lead development.
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Table 4.1 Summary of fragment hits found in the binding pocket of the SC monomers (Chain A and Chain B) in crystals of P1 or P21 space
groups.
Chain A
Space
group

Subsite I

Accessible
P1
11 fragment hits were found

Chain B
Subsite II

Subsite I

Occupied,

Partially occupied,

by a loop from the symmetry by a Glu residue of a Accessible.
related molecule.
symmetry related molecule.
No fragment hit was found.
No fragment hit was found.

6 fragment hits were found.

Accessible,
P21

but slightly compressed by a Accessible.
symmetry related molecule.
No fragment hit was found.
No fragment hit was found.

Subsite II

Occupied,
Accessible
1 fragment hit was found.

by a loop from the symmetry
related molecule.
No fragment hit was found.
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Table 4.2 Fragment compounds identified to bind to the subsite I of the SC.
Plat
e
No.

Well

ID

1

1

1C

2

1

3

Chemical
structures

Space
group

Binds to
Chain A

Binds to
Chain B

ZT0007

P1

Y

Y

4G

ZT0250

P1

Y

N

1

10H

ZT0602

P1

Y

N

4

1

11H

ZT0428

P1

Y

N

5

2

1G

ZT0447

P1

Y

N

6

2

6E

ZT0445

P1

Y

N

7

2

7B

ZT0082

P1

Y

N

8

3

2H

ZT0784

P1

N

Y

9

3

7A

ZT0273

P1

N

Y

10

3

8E

ZT0642

P21

N

Y

11

3

9H

ZT0817

P1

Y

Y
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Table 4.2 (continued) Fragment hits identified to bind to the subsite I of the SC.
Plat
Chemical
Space Binds to Binds to
e
Well
ID
structures
group Chain A Chain B
No.
12

4

3B

ZT0694

P1

N

Y

13

4

3F

ZT0789

P1

N

Y

14

4

6G

ZT0860

P1

N

Y

15

4

8D

ZT0773

P1

N

Y

16

4

7G

ZT0834

P1

Y

N

17

4

8G

ZT0835

P1

Y

N

Y: yes; N: no.
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Table 4.3 Data collection and refinement statistics of E. coli SC in complex with fragment hits.
Name
Data collection
Space group

SCZT0007

SCZT0835*

SCZT0250

SCZT0602

SCZT0428

SCZT0447

P1

P1

P1

P1

P1

P1

a, b, c (Å)/α, β, γ (°)
41.16,
64.60, 71.99/
74.61, 83.32, 84.90

a, b, c (Å)/α, β, γ (°)
40.92,
65.01, 72.02/
74.15, 83.37, 85.12

a, b, c (Å)/α, β, γ (°)
40.72,
64.04,
71.70/
73.88, 82.29, 84.03

a, b, c (Å)/α, β, γ (°)
40.74, 64.51, 71.72/
74.01, 83.21, 84.54

a, b, c (Å)/α, β, γ (°)
40.87,
64.38, 71.67/
73.97, 82.57, 84.60

a, b, c (Å)/α, β, γ (°)
40.88,
64.67, 72.02/
73.97, 83.55, 84.36

28.75-1.67(1.76-1.67)

53.97- 2.03 (2.14-2.03)

28.86 - 1.80 (1.90-1.80)

30.38-1.73 (1.82-1.73)

30.33- 2.00 (2.11-2.00)

30.51 - 1.70 (1.79-1.70)

5.6(40.3)
234038
79710 (11444)
13.3 (2.6)
96.9 (95.4)
2.9 (3.0)

5.3 (31)
167496
42901 (6002)
18.7 (4.3)
94.1 (90.3)
3.9 (3.6)

6.4(39.9)
235693
61187 (8833)
14.3 (3.2)
91.7 (91.9)
2.0 (1.9)

6.7(55.1)
242483
66608 (8933)
9.9 (2.1)
91.7 (84.2)
3.6 (3.6)

6.2(23.4)
144280
39267 (4918)
14.4 (6.2)
83.6 (71.8)
3.7 (3.5)

4.8(32.8)
242187
64167 (9074)
15.2 (3.4)
83.0 (80.4)
3.8 (3.7)

Resolution (Å)

27.72 -1.67 (1.71-1.67)

53.97 -2.03 (2.08-2.03)

28.32 - 1.80 (1.85-1.80)

29.91 -1.73 (1.78-1.73)

28.08 -2.00 (2.05-2.00)

28.72 - 1.70 (1.74-1.70)

Rwork/Rfree (%)

17.7(25.6)/22.3(31.6) 23.3(26.8)/30.1(36.3) 18.6(26.4)/22.4(30.3) 24.8(35.5)/29.2(44) 20.2(28.0)/26.4(29.6) 22.9(33.3)/27.4(41.9)

Cell dimensions
Resolution (Å)
Rmerge (%)
No. of Reflections
Unique Reflections

Mean I/σ(I)
Completeness
Multiplicity
Refinement

R.m.s
Bond
lengths 0.0206
0.0115
0.0068
0.0098
0.0084
0.0084
Bond angles (º) 2.1209
1.4105
1.2819
1.4687
1.2873
1.3279
B-factors
M. Chain
16.7
21.4
18.5
20.6
19.3
19.4
S. Chain & Water
23.4
24.8
23.3
24.1
23.2
22.8
Ligands**
64.4
50
49.7
41.5
43.3
35.6
Ramachandran
0.43%
0.84 %
0.43 %
0.57 %
0.28 %
0.43 %
Plot Outliers
Values for data in the highest resolution shell are given in parentheses.
Diffraction data collected at BeamlineMX1, Australian Synchrotron, at the wavelength of 0.95 Å Diffraction data were processed with MOSFLM and SCALA.
*Diffraction data collected at home-sourced X-ray generator at the wavelength of 1.5418 Å. **Ligands refer to the fragment compounds bound with Chain A.
91

Table 4.3 (continued) Data collection and refinement statistics of E. coli SC in complex with fragment hits.
Name
SCZT0445
Data collection
Space group
P1

SCZT0784

SCZT0273

SCZT0642

SCZT0817

P1

P1

P1

P21

P1

a, b, c (Å)/α, β, γ (°)
40.88,
64.78,
72.59/
73.91, 84.51, 84.89

a, b, c (Å)/α, β, γ (°)
40.75,
64.33, 72.17/
74.05, 82.47, 84.15

a, b, c (Å)/α, β, γ (°)
41.21,
64.67,
71.92/
74.46, 83.50, 84.94

a, b, c (Å)/α, β, γ (°)
41.09,
64.55, 72.01/
74.25, 83.51, 84.60

a, b, c (Å)/α, β, γ (°)
79.73,
68.07,
82.72/
90.00, 115.81, 90.00

a, b, c (Å)/α, β, γ (°)
40.89, 64.65, 71.96/
74.01, 82.86, 84.10

28.90-1.97(2.08-1.97)

30.19- 2.05 (2.16-2.05)

29.23 - 2.00 (2.11-2.00)

29.07-1.83 (1.93-1.83)

30.5- 2.30 (2.42-2.30)

30.34 - 1.8 (1.90-1.80)

5.6(19.1)
153662
42650 (6264)
12.7 (6.4)
84.8 (85.2)
3.6 (3.3)

12.8 (59)
158461
40969 (5896)
9.2 (2.2)
93.7 (92.7)
3.9 (3.7)

4.2(15.3)
80216
41193 (5348)
11.8 (6.8)
85.9 (76.4)
1.9 (1.9)

4.4(20.4)
202200
52413 (6975)
17.8 (6.5)
84.2 (77.0)
3.9 (3.8)

11.2 (61.3)
204523
34671 (4631)
11.4 (2.3)
97.2 (89.2)
5.9 (5.2)

7.2(41.4)
226644
59986 (8586)
9.2 (2.5)
92.3 (90.3)
3.8 (3.5)

Resolution (Å)

28.90 -1.97 (2.02-1.97)

30.19 -2.05 (2.10-2.05)

28.01 - 2.00 (2.05-2.00)

29.07 -1.83 (1.877-1.83)

28.38 -2.5 (2.35-2.3)

27.6 - 1.80 (1.85-1.80)

Rwork/Rfree
R.m.s
Bond lengths
Å
Bond
angles
B-factors
M. Chain

23.5(30.8)/30.5(42)

20.1(26.2)/24.8(31.2

21.1(25.2)/25.5(28.4)

22.1(30.3)/28.5(37.1

28.4(34.5)/34.4(34.8) 26.4(34.1)/30.4(41.5

0.0078
1.3037

0.01
1.4456

0.0063
1.1794

0.0092
1.3732

0.0049
0.9546

Cell dimensions

Resolution
RÅmerge (%)
No. of Reflections
Unique Reflections

Mean I/σ(I)
Completeness
Multiplicity
Refinement

SCZT0082

0.0114
1.5433

20.2
21.2
16.8
20.1
34.8
20.6
S. Chain & Water 22.9
25.0
19.28
24.2
35.5
24.1
Ligands**
36.3
62.5
27.4
29.1
86.7
65.7
Ramachandran
0.56%
0.70 %
0.28 %
0.42 %
0.87 %
0.84 %
Plot Outliers
Values for data in the highest resolution shell are given in parentheses.
Diffraction data collected at BeamlineMX1, Australian Synchrotron, at the wavelength of 0.95 Å Diffraction data were processed with MOSFLM and SCALA.
*Diffraction data collected at home-sourced X-ray generator at the wavelength of 1.5418 Å. **Ligands refer to the fragment compounds bound with Chain A
(Chain B in the case of SCZT0642).
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Table 4.3 (continued) Data collection and refinement statistics of E. coli SC in complex with fragment hits.
Name
Accession code
Data collection
Space group
Cell dimensions
Resolution (Å)
Rmerge (%)
No. of Reflections
Unique Reflections

Mean I/σ(I)
Completeness
Multiplicity
Refinement
Resolution (Å)
Rwork/Rfree
R.m.s
Bond
lengths
Å
Bond angles (º)
B-factors
M. Chain

SCZT0694
unavailable

SCZT0789
unavailable

SCZT0860
unavailable

SCZT0773
unavailable

SCZT0834*
unavailable

P1

P1

P1

P1

P1

a, b, c (Å)/α, β, γ (°)
41.11,
64.62, 71.97/
74.77, 83.50, 84.96

a, b, c (Å)/α, β, γ (°)
40.85, 64.36, 71.82/
74.31, 83.10, 84.24

a, b, c (Å)/α, β, γ (°)
41.05,
64.77,
72.07/
74.33, 83.37, 85.08

a, b, c (Å)/α, β, γ (°)
40.97,
64.68,
72.22/
74.50, 83.55, 84.99

a, b, c (Å)/α, β, γ (°)
41.01, 64.76, 72.07/
74.30, 83.08, 84.90

29.25-1.80(1.90-1.80)

30.32- 2.10 (2.21-2.10)

29.24 - 1.89 (1.99-1.89)

29.18-1.90 (2.00-1.90)

53.78- 2.10 (2.21-2.10)

4.3(16)
191150
55546 (8292)
17.3 (6.5)
84.6 (86.7)
3.4 (3.4)

7.0 (25.7)
144776
37517 (5427)
15.1 (4.7)
92.1 (90.8)
3.9 (3.7)

6.9(36.9)
196211
52282 (7174)
13.2 (3.2)
92.1 (86.8)
3.8 (3.4)

4.4(12.3)
178727
46580 (5411)
21.3 (10.8)
83.4 (66.2)
3.8 (3.7)

11.8 (60.5)
151631
38819 (5539)
10.0 (2.7)
94.0 (91.6)
3.9 (3.8)

29.25 -1.80 (1.85- 28.94 -2.10 (2.15- 28.67 - 1.89 (1.94- 27.99 -1.90 (1.95- 41.16 -2.10 (2.1520.9(24.1)/26.3(32.3) 19.8(20.7)/23.5(26.3) 19.8(24.7)/24.5(30.1) 20.9(33.0)/25.0(36.6) 23.1(29.0)/29.0(36.5)
0.0079
1.2917

0.0064
1.1450

0.0083
1.3213

0.0085
1.2818

0.0065
1.2044

Ligands**

15.7
20.1
19.9

20.1
23.1
16

20.6
24.6
47.8

16.5
20.1
29.4

21.1
24.0
64.1

Ramachandran
Plot Outliers

0.28%

0.28 %

0.28 %

0.56 %

0.42 %

S. Chain & Water

Values for data in the highest resolution shell are given in parentheses.
Diffraction data collected at BeamlineMX1, Australian Synchrotron, at the wavelength of 0.95 Å Diffraction data were processed with MOSFLM and SCALA.
*Diffraction data collected at home-sourced X-ray generator at the wavelength of 1.5418 Å. **Ligands refer to the fragment compounds bound with Chain A.
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Figure 4.1 Fragment hit 3,4-difluorobenzamide found in subsite I of Chain A
(Fragment ID: ZT0602). The SC is shown with carbon atoms coloured white and the
carbon atoms of the fragment hit coloured light green. Non-carbon atoms are in CPK
colours. Wire basket represents 2mFo-DFc electron density map contoured at 1 σ. Red
spheres represent water molecules.

Figure 4.2 Fragment hit 5-chloroindoline-2,3-dione found in subsite I of Chain A
(Fragment ID: ZT0250). The SC is shown with carbon atoms coloured white and the
carbon atoms of the fragment hit coloured light green. Non-carbon atoms are in CPK
colours. Wire basket represents 2mFo-DFc electron density map contoured at 1 σ. Red
spheres represent water molecules.
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Figure 4.3 Fragment hit 5-chloro-1H-benzo[d]imidazole found in subsite I of Chain A
(Fragment ID: ZT0082). The SC is shown with carbon atoms coloured white and the
carbon atoms of the fragment hit coloured light green. Non-carbon atoms are in CPK
colours. Wire basket represents 2mFo-DFc electron density map contoured at 1 σ. Red
spheres represent water molecules.

Figure 4.4 Fragment hit 4-bromobenzamide found in the subsite I of Chain A
(Fragment ID: ZT0007). SC is shown with carbon atoms coloured white and the carbon
atoms of the fragment hit coloured light green. Non-carbon atoms are in CPK colours.
Wire basket represents 2mFo-DFc electron density map contoured at 1 σ. Red spheres
represent water molecules.
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Figure 4.5 Fragment hit 3-iodobenzoic acid found in subsite I of Chain B (crystal space
group P21, Fragment ID: ZT0642). SC is shown with carbon atoms coloured white and
the carbon atoms of the fragment hit coloured light green. Non-carbon atoms are in
CPK colours. Wire basket represents 2mFo-DFc electron density map contoured at 1 σ.
Red spheres represent water molecules.

Figure 4.6 Fragment hit 6-nitro-1H-indazole found in subsite I of Chain A (Fragment
ID: ZT0447). The SC is shown with carbon atoms coloured white and the carbon atoms
of the fragment hit coloured light green. Non-carbon atoms are in CPK colours. Wire
basket represents 2mFo-DFc electron density map contoured at 1 σ. Red spheres
represent water molecules. Red dashed lines represent H-bonds.
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Figure 4.7 Fragment hit 5-nitro-1H-indole found in subsite I of Chain A (Fragment ID:
ZT0445). The SC is shown with carbon atoms coloured white and the carbon atoms of
the fragment hit coloured light green. Non-carbon atoms are in CPK colours. Wire
basket represents 2mFo-DFc electron density map contoured at 1 σ. Red spheres
represent water molecules. Red dashed lines represent H-bonds.

Figure 4.8 Fragment hit 1-(4-nitrophenyl)piperazine found in subsite I of Chain A
(Fragment ID: ZT0834). The SC is shown with carbon atoms coloured white and the
carbon atoms of the fragment hit coloured light green. Non-carbon atoms are in CPK
colours. Wire basket represents 2mFo-DFc electron density map contoured at 1 σ. Red
spheres represent water molecules. Red dashed lines represent H-bonds.
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Figure 4.9 Fragment hit 4-methyl-5-nitropyridin-2-amine found in subsite I of Chain A
(Fragment ID: ZT0428). The SC is shown with carbon atoms coloured white and the
carbon atoms of the fragment hit coloured light green. Non-carbon atoms are in CPK
colours. Wire basket represents 2mFo-DFc electron density map contoured at 1 σ. Red
spheres represent water molecules. Red dashed lines represent H-bonds.

Figure 4.10 Fragment hit 1-(4-(4-hydroxyphenyl)piperazin-1-yl)ethanone found in
subsite I of Chain A (Fragment ID: ZT0835). The SC is shown with carbon atoms
coloured white and the carbon atoms of the fragment hit coloured light green. Noncarbon atoms are in CPK colours. Wire basket represents 2mFo-DFc electron density
map contoured at 1 σ. Red spheres represent water molecules. Red dashed lines
represent H-bonds.
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Table 4.4 Binding affinities of fragment hits based on crystallographic occupancy and lipoligand efficiency (LLEAT) analysis.
ΔG at
ΔG*,
LogD
Fragmen Plate
Ligand
B- T172 Oγ Occupan
300K,
HA
LE,
ΔGlipo,
Well
Kd, mM
(pH
kcal/mo LLEAT
kcal/mol
t hits
No.
factor
B-factor cy
kcal/mo C
kcal/mol
l
7.2)
l
1

1C

35.45

12.13

0.34

9.61

-2.78

10.0
0

0.28

1.47

-2.02

-0.76

0.19

1

4G

39.35

5.49

0.14

30.84

-2.08

12.0
0

0.17

1.12

-1.54

-0.54

0.15

1

10H

38.28

14.07

0.37

8.60

-2.85

11.0
0

0.26

1.08

-1.49

-1.36

0.23

1

11H

42.86

9.40

0.22

17.80

-2.41

11.0
0

0.22

0.94

-1.30

-1.12

0.21

2

1G

24.64

16.43

0.67

2.50

-3.59

12.0
0

0.30

1.35

-1.86

-1.73

0.25

2

6E

33.66

14.38

0.43

6.70

-3.00

12.0
0

0.25

-0.48

0.66

-3.66

0.41

2

7B

66.21

12.14

0.18

22.27

-2.28

12.0
0

0.19

2.00

-2.76

0.48

0.07

3

2H

n/a

n/a

n/a

n/a

n/a

15.0
0

n/a

3.59

n/a

n/a

n/a

3

7A

n/a

n/a

n/a

n/a

n/a

16.0
0

n/a

2.29

n/a

n/a

n/a

1
2
3
4
5
6
7
8
9
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Table 4.4 (continued) Binding affinities of fragment hits based on crystallographic occupancy and lipoligand efficiency (LLEAT) analysis.
Fragment
hits

10

Kd,
mM

ΔG at
300K,
HA
kcal/mo C
l

1.16

-0.69

n/a

13.16

0.18

22.09

n/a

n/a

n/a

3F

n/a

n/a

4

6G

n/a

4

8D

4
4

Pla
te
No
.

Ligand
Well
factor

3

8E

24.65

28.61

3

9H

71.31

4

3B

4

LE,
LogD
kcal/mo (pH
l
7.2)

ΔGlipo,
kcal/mol

ΔG*,
kcal/mol

LLEAT

10.0
0

n/a

-0.50

0.68

n/a

n/a

-2.28

14.0
0

0.16

2.93

-4.04

1.76

-0.02

n/a

n/a

12.0
0

n/a

-2.05

n/a

n/a

n/a

n/a

n/a

n/a

13.0
0

n/a

1.04

n/a

n/a

n/a

n/a

n/a

n/a

n/a

11.0
0

n/a

2.77

n/a

n/a

n/a

n/a

n/a

n/a

n/a

n/a

11.0
0

n/a

-2.05

n/a

n/a

n/a

7G

43.62

13.85

0.32

5.37

-3.13

15.0
0

0.21

-0.31

0.43

-3.55

0.35

8G

50.09

15.95

0.32

5.35

-3.13

16.0
0

0.20

0.52

-0.72

-2.41

0.26

B- T172 Oγ Occupan
B-factor cy

11
12
13

14
15

16
17
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Chapter 5
Fragment development
and binding characterization
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5.1 Introduction
5.1.1 Design strategy for fragment development
Three classical strategies for fragment development: expansion, merging and
tethering, have been explored. Expansion refers to finding chemical structures that
contain the scaffold of a fragment hit. Merging refers to chemical structures that are
composites of moieties of two or more fragment hits. Tethering, however, requires two
fragment hits bound respectively to individual sites adjacent to each other.
The three strategies were used in the search for candidate compounds from the UCSF
ZINC library. The ZINC Database contains commercially available compounds for
structure-based virtual screening.136 It currently contains about 21 million compounds
that are commercially available, provided in ready-to-dock 3D-structure formats with
molecules represented in biologically relevant forms.136 Substructure searches and
similarity searches based on the fragment chemical structures were carried out to
identify candidate binders.
5.1.2 Prediction of ligand binding pose using molecular docking
Molecular docking was applied in pose prediction. Most scoring functions for
docking programs are empirical and are derived from the affinity of known inhibitors to
their targets. Since most known targets are enzymes, membrane transporters and/or Gprotein coupled receptors, there is bias toward these targets. The SC, on the other hand,
is a hub mediating protein-protein interaction, and therefore the aforementioned
empirical functions may be biased against such a distinct class of targets. Therefore,
UCSF DOCK6, which applies force-field based functions in scoring, was selected.137
Grid score is a fast, force field-based scoring function that was used as the primary
metric used to rank initial hits. Grid score is a fast force field-based scoring function
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accounting for van der Waals (VDW) interaction and electrostatic interactions. The
Hawkins GB/SA score is used as a secondary ranking metric. Amber score138 was used
as an additional ranking metric. The Amber score is obtained through a molecular
dynamics simulation of the ligand-receptor complex and molecular mechanics
calculation of the binding energy with GB/SA solvation.
Chimera was used for molecular visualization. It affords the visualization of docked
ligands in various poses139 and can cluster predicted binding poses based on interactions
with adjacent amino acid residues.
Fragment hits described in Chapter 4 were docked to the SC and analysed based on
the scores (with emphasis on the Amber score). Their binding poses were visually
inspected. Substructure and similarity searches were carried out and the candidate
compounds were computationally docked and analysed. Several compounds were
purchased and tested using the fluorescence polarization assay to determine the IC50
values and the crystallographic binding pose.
5.1.3 Repetitive search for optimal binder of similar scaffold
Hits confirmed by the fluorescence polarization assay were put through the
substructure search process to find similar candidates for further testing. Since
molecular docking is a prediction tool of limited precision, both in terms of the binding
poses and the ranking of ligand affinities, initial hits were expected to be weak binders
and further searches based on their scaffolds were carried out in the search for similar
compounds with potentially higher affinity. This approach may balance the bias in the
docking program and its scoring functions and allow the testing of a structurally diverse
range of candidates.
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5.2 Materials and methods
5.2.1 Chemo-informatics
Fragment hits were paired and merged to yield larger scaffolds. These scaffolds were
used in the search for similar compounds that might fully occupy subsite I. Candidates
with molecular weight < 300 Dalton or with scaffolds > 200 Da and overall molecular
weight < 350 Dalton were docked with Grid score as a primary score to generate 50 top
poses which are clustered and the cluster heads were in turn scored with Hawkins
GB/SA score as a secondary score. The top scored compounds were Amber scored and
the manually selected ones were bought for testing.138
Derivatives based on the fragment scaffold as substructures were narrowed to those
with molecular weights in the range 200 Dalton to 300 Dalton. They were then docked
and scored in a way similar to the merging strategy. The manually selected derivatives
were purchased for testing.
Molecular docking was performed using UCSF DOCK 6 software.137 The receptor
was prepared by removing all crystallographic water molecules in the sidling clamp,
except for a structurally conserved water molecule near residue M362. The receptor
structure was truncated of residues within 15 Å of the binding pocket. Hydrogen atoms
were added and partial charges were assigned using Chimera139. Ligands were prepared
using UCSF Chimera or obtained from the UCSF ZINC library. Spheres for ligand
orientation were generated using the identified fragment binders. A grid map for scoring
was generated encompassing residues within 15 Å of the spheres. Docking was carried
out using Grid score as the primary score and GB/SA Hawkins score as a secondary
scoring method. The top 50 poses were clustered and the top 10 cluster heads assessed
using the secondary scoring method. Additionally, Amber scoring138 was performed
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with 100 steps of minimization, 3000 steps and another 100 minimization steps, and
each step corresponds to 2 fs. In all cases, ligand flexibility was allowed with the
receptor kept rigid. Selected molecules were checked for their commercial availability
and some of these were acquired for testing.
5.2.2 Organic chemistry
Compounds (>95% purity) were sourced from commercial suppliers. Several
derivatives based on the tetrahydrocarbazole scaffold were synthesized by Dr. Louise
Whittell under the supervision of Dr. Michael Kelso from the School of Chemistry,
University of Wollongong. The synthesized compounds were of > 95% purity as
confirmed by mass spectrometry.
5.2.3 Fluorescence polarization assay
See Chapter 3.
5.2.4 Crystallization, co-crystallization and soaking of compounds
See Chapter 2 for method used in crystallization of the E. coli SC and the soaking of
compounds. Co-crystallization was performed to obtain a co-crystal of the compound
P1A7 with the sliding clamp. 0.5 µL of 100 mM of P1A7 pre-dissolved in DMSO were
added to 10 µL solution of the SC protein (53 mg/ml) and incubated for 10 min.
5.2.5 Data collection, processing, structural solution and refinement.
See Chapter 2.
5.3 Results and Discussion
5.3.1 Chemo-informatics and molecular docking
About 25,000 candidate compounds were drawn from the ZINC library based on the
fragment hits. These were docked into the subsite I of the SC. Initially, 45 candidates
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within the top 500 candidates ranked by Amber score were selected based on their
chemical diversity and availability and purchased. A carbazole derivative (see 5.3.2.3)
was found that had weak affinity. Subsequently, a tetrahydrocaobazole scaffold was
designed based on the carbazole scaffold and derivatives from substructure searches
were bought and tested (see 5.3.2.4). Another scaffold was designed and substructure
searches were performed in order to select candidates based on chemical diversity and
found other hits with these two different scaffolds (see 5.3.2.1 and 5.3.2.2).
5.3.2 Fragment development and characterization.
In total, about 300 candidate compounds (including the 45 initial candidates
identified by docking and the additional candidates selected by structural similarity
searches) were purchased and their IC50 values determined by the FP assays, which
were then corrected of ligand depletion to yield Ki values.127 Some hits with affinities <
1 mM were selected and their structures in complex with the SC were determined.
Many positive hits based on four different scaffolds were obtained from this repetitive
search for optimal binders. They are discussed below.
5.3.2.1 P1B8 (4'-fluorobiphenyl-4-carboxylic acid)
One candidate, designated P1B8 (4'-fluorobiphenyl-4-carboxylic acid) as an
expanded fragment, was found to bind to the SC with an IC50 of about ~500 µM and Ki
value of ~283 µM (Figure 5.1). High uncertainty was attributed to these values due to
the inhibition of tracer binding rising to only ~50% at the maximum concentration.
(Curve fitting was performed using 100% as the top inhibition rate.)
The crystal structure of P1B8 with the SC was solved (crystallographic data in Table
5.1). As expected for merged fragments, P1B8 occupies all of subsite I, forming a salt
bridge with R152 and an H-bond with the side chain of Y154 (Figure 5.2). No
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significant changes in the conformations of residues in the binding pocket were
observed except for the Chi2 angle of M362. Two conformations of the M362 side chain
were found within the crystal structure. Chi2 of 177° corresponds to a "closed"
conformation of M362 as observed in a native crystal structure as aforementioned. Chi2
of -56° corresponds to an "open" or "half-open" conformation of M362 where the
passage from subsite I to subsite II is accessible.
Since the salt-bridge and H-bond between the compound and the R152 and Y154
side chains were the major difference to the binding of the fragment compounds, it's
likely that these interactions caused the slanted pose of the biphenyl ring and triggered
open the gating residue M362.
Although P1B8 may be a good candidate for lead development, further development
was hampered by limited commercial availability of derivatives in which potential
substitutions on the biphenyl moiety that will not interfere with the favourable
interactions P1B8 makes with the SC. Therefore investigation of P1B8 was
discontinued.
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Figure 5.1 Dose-response curve (fitted using variable slope) for binding of P1B8 (4'fluorobiphenyl-4-carboxylic acid), as an expansion product of fragment hit ZT0602,
inhibiting the fluorescent tracer binding to the SC. Error bars represent ± 1 standard
deviation (n=2). Where not visible, error bars are within the markers.
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Figure 5.2 P1B8 (4'-fluorobiphenyl-4-carboxylic acid) bound to chain A of the SC
(space group P21). The SC is shown with carbon atoms coloured white and the carbon
atoms of the ligand coloured light green. Non-carbon atoms are in CPK colours. Wire
basket represents (2mFo-DFc) electron density map contoured at 1 σ. Red spheres
represent water molecules. Red dashed lines represent H-bonds.
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Table 5.1 Data collection and refinement statistics of E. coli SC in complex with and
P1B8(4'-fluorobiphenyl-4-carboxylic acid).

Name
Data collection
Space group
Cell dimensions
Resolution (Å)
Rmerge (%)
No. of Reflections
Unique Reflections
Mean I/σ(I)
Completeness (%)
Multiplicity
Refinement
Resolution (Å)
Rwork/Rfree (%)
R.m.s deviations
Bond lengths (Å)
Bond angles (º)
B-factors
M. Chain
S. Chain & Water
Ligands*
Ramachandran Plot Outliers

SCP1B8
P21
a, b, c (Å)/α, β, γ (°)
79.90, 67.16, 81.06/90.00, 114.11, 90.00
30.50-1.70 (1.79-1.70)
9.7(68.3)
603665
86092 (12490)
9.2 (2.4)
99.9 (99.8)
7.0 (6.9)
30.17 -1.70 (1.74-1.70)
25.7(30.1)/29.7(35.5)
0.0079
1.2868
22.2
26.4
39.8
0.57 %

The value for the highest resolution shell is given in parentheses.
Diffraction data collected at BeamlineMX1, Australian Synchrotron, at
wavelength 0.95 Å; Diffraction data were processed with MOSFLM and
SCALA.
*Ligands refer to the P1B8 with Chain A.
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5.3.2.2 The phenylpiperazine scaffold
Two fragment hits (ZT0834 and ZT0835) had a phenylpiperazine scaffold. This
scaffold was used in a substructure search for commercially available candidates for
testing. Derivatives with halogen atoms on the phenyl ring were visually inspected since
the such sub-structures were found in many fragment hits.
Selected candidates were purchased and their IC50 values and the Ki values
determined after correction for ligand depletion. The affinity values were calculated
with a degree of uncertainty since the inhibition rate of the tracer binding only achieved
~50% at the maximum concentration. The curve fitting was performed using 100% as
the top inhibition rate.
Two compounds were found with ~500 µM affinity (P5aD8 and P5aB3, Figure 5.35.4, Table 5.3). The binding poses of the two phenylpiperazine–containing compounds
were determined by X-ray crystallography (Figure 5.5-5.6, crystallographic data in
Table 5.2). The structures showed that, unexpectedly, the piperazine rings were not
positioned within the binding pocket but rather above it (Figure 5.5-5.6). Subsite I was
partially occupied by the halogenated phenyl ring and either an aldehyde- or nitrosubstituent on the phenyl ring. The halogen atom was situated in the previously
identified “halogen-binding pocket”. The aldehyde group of P5aB3 (but not the nitro
group of P5aD8) formed an H-bond with the T172 side chain. There are no other
identifiable interactions that may have limited their binding affinity.
In comparison with the fragment hits with the phenylpiperazine scaffold (ZT0834
and ZT0835, Figure 4.8 and Figure 4.10), neither P5aD8 nor P5aB3 were bound with
their respective nitro or aldehyde groups within hydrogen bonding distance of the S346
side chain. Additionally, the binding pocket adopts a slightly curved geometry caused
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by the presence of P352 and may therefore favour ligands with flexibility higher than
that of rigid rings. Binding of P5aD8 or P5aB3 to the SC suggests that halogen
substitutions on aromatic rings may be optimal at the meta position as opposed to the
para position.
Other candidates with similar scaffolds showed Ki values over 500 µM (Table 5.3).
Owing to the low affinity and the unexpected binding pose of P5aD8 and P5aB3,
investigation of the phenylpiperazine scaffold was discontinued.
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Figure 5.3 Dose-response curve (fitted using variable slope) of P5aD8 (1-(4-(4-chloro2-nitrophenyl)piperazin-1-yl)ethanone) inhibiting the fluorescent tracer binding to the
SC. Error bars represent ± 1 standard deviation (n=2).
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Figure 5.4 Dose-response curve (fitted using variable slope) of P5aB3 (methyl 4-(4chloro-2-formylphenyl)piperazine-1-carboxylate) inhibiting the fluorescent tracer
binding to the SC. Error bars represent ± 1 standard deviation (n=2).
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Figure 5.5 P5aD8 (1-(4-(4-chloro-2-nitrophenyl)piperazin-1-yl)ethanone) bound in the
subsite I of Chain A of a crystal of P1 space group. The SC is shown with carbon atoms
coloured white and the carbon atoms of the ligand coloured light green. Non-carbon
atoms are in CPK colours. Wire basket represents (2mFo-DFc) electron density map
contoured at 1 σ.
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Figure 5.6 P5aB3 (methyl 4-(4-chloro-2-formylphenyl)piperazine-1-carboxylate)
bound in the subsite I of Chain A of a crystal of P1 space group. The SC is shown with
carbon atoms coloured white and the carbon atoms of the ligand coloured light green.
Non-carbon atoms are in CPK colours. Wire basket represents (2mFo-DFc) electron
density map contoured at 1 σ. Red dashed lines represent H-bonds.
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Table 5.2 Data collection and refinement statistics of E. coli SC in complex with and
P5aD8 and P5aB3, respectively.
SCP5aD8

Name
Data collection
Space group

a, b, c (Å)/α, β, γ (°)

SCP5aB3
P1
a, b, c (Å)/α, β, γ (°)

41.07, 64.48, 71.92/74.16, 82.77, 41.08, 64.49, 72.14/73.87, 82.57,
84.84
84.69

Cell dimensions
Resolution (Å)
Rmerge (%)
No. of Reflections
Unique Reflections
Mean I/σ(I)
Completeness (%)
Multiplicity
Refinement

50.00-2.55 (2.64-2.55)
7.1(35.7)
56937
23073 (2078)
14.9 (2.4)
94.6 (91.4)
2.5 (2.0)

50.00-2.30 (2.38-2.30)
6.2(34.8)
112660
31244 (2509)
20.6 (2.8)
94.4 (80.5)
3.6 (3.2)

Resolution (Å)
Rwork/Rfree (%)

40.96 -2.55 (2.61-2.55)
21.5(26.3)/29.8(38.9)

40.87 -2.29 (2.34-2.29)
22.7(26.7)/28.0(44.2)

0.0057
0.9295

0.0055
0.9095

21.0
22.0
33.3

19.1
20.0
41.7

0.70 %

0.55 %

R.m.s deviations
Bond lengths (Å)
Bond angles (º)
B-factors
M. Chain
S. Chain & Water
Ligand*
Ramachandran
Outliers

Plot

The value for the highest resolution shell is given in parentheses.
*Diffraction data were collected at home-sourced X-ray generator at the wavelength of
1.5418 Å and processed with HKL2000.
*Ligand refers to P5aD8 and P5aB3 bound with Chain A, respectively.

116

Table 5.3 Summary data of developed fragments with the phenylpiperazine scaffold.
Plate
No.

Well

CHEMISTRY

IC50, µm

Ki,
µM

ΔG at
300K,
kcal/mol

HAC

LE,
kcal/mo
l

LogD
(pH
7.2)

ΔGlipo,
kcal/mo
l

ΔG*,
kcal/mol

LLEAT

1554

863

-4.22

27

0.16

2.32

-3.19

-1.03

0.15
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-4.58

19

0.24

1.81
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-2.08

0.22
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1.78
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O
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2.17
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5.3.2.3. The carbazole scaffold
A number of fragment hits had indole, indazole or imidazole rings that share
common geometric properties. A search of commercially available compounds with
these substructures identified a carbazole scaffold. Carbazole derivatives with halogen
(mostly chlorine) substitutions on the carbazole ring were obtained.
Selected candidates were obtained and their IC50 values and the Ki values determined
as described previously. as noted previously, affinity values were calculated with some
uncertainty due to the inhibition rate of the tracer binding peaking at ~50% at the
maximum concentration. The curve fitting was performed using 100% as the top
inhibition rate. These compounds showed weak affinity (Ki~500 µM). The positive hits
are listed in the Table 5.5. The hits featured two additional substitutions, one at the
indole nitrogen and the other on the opposite ring, as indicated in Figure 5.7.
The dose-response curve of the tightest-binding carbazole compound tested, P1A7, is
shown in Figure 5.8. To relate the affinity data to structure, the SC crystal structure in
complex withP1A7 ((R)-3-chloro-9-(oxiran-2-ylmethyl)-9H-carbazole) was determined
(Figure 5.9).The crystallographic data are shown in Table 5.4. The binding of P1A7 is
similar to the fragment hit ZT0082 containing an imidazole ring. P1A7 has an aromatic
ring additional to that observed in ZT0082 and an epoxy group. The gating residue,
M362, displays two conformations in the crystal structure. The Chi2 angles correspond
to those previously identified as "closed" and "open" conformations (see Chapter 3).
However, the epoxy group, the natural position for chemical modification of P1A7, was
not observed to extend toward M362 (and hence not toward the passage to subsite II).
The carbazole scaffold was therefore discontinued in further lead development.

119

H
N

O2N

NO2
N

N
H

N

Cl

N
H

R1
N

Cl

R2

Figure 5.7 The design of the carbazole scaffold based on the fragment hits. Various
substituents at the R1 and R2 positions were tested.
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Figure 5.8 Dose-response curve (fitted using variable slope) of P1A7 ((R)-3-chloro-9(oxiran-2-ylmethyl)-9H-carbazole) inhibiting the fluorescent tracer binding to the SC.
Error bars represent ± 1 standard deviation (n=2).
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Figure 5.9 P1A7 ((R)-3-chloro-9-(oxiran-2-ylmethyl)-9H-carbazole) bound in the
subsite I of Chain A of a beta-clamp crystal (P1 space group). The SC is shown with
carbon atoms coloured white and the carbon atoms of the ligand coloured light green.
Non-carbon atoms are in CPK colours. Wire basket represents (2mFo-DFc) electron
density map contoured at 1 σ.
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Table 5.4. Data collection and refinement statistics of E. coli SC in complex with P1A7.
Name
Data collection
Space group
Cell dimensions
Resolution (Å)
Rmerge (%)
No. of Reflections
Unique Reflections
Mean I/σ(I)
Completeness (%)
Multiplicity
Refinement
Resolution (Å)
Rwork/Rfree (%)
R.m.s deviations
Bond lengths (Å)
Bond angles (º)
B-factors
M. Chain
S. Chain & Water
Ligand*
Ramachandran Plot Outliers

SCP1A7
P1
a, b, c (Å)/α, β, γ (°)
41.01, 64.92, 71.94/74.44, 83.31, 85.28
50.00-1.93 (2.00-1.93)
4.5(18.9)
181848
53392 (4852)
23.1 (6.4)
93.8 (90.7)
3.4 (3.3)
41.19 -1.93 (1.98-1.93)
24.7(36.0)/30.9(38.5)
0.0070
1.2673
23.5
26.3
66.0
0.57 %

The value for the highest resolution shell is given in parentheses.
*Diffraction data were collected at home-sourced X-ray generator at the wavelength of
1.5418 Å and processed with HKL2000.
*Ligand refers to theP1A7bound with Chain A.
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Table 5.5 Summary data of developed fragments with the carbazole scaffold.
Plate
No.
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885
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1.51
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0.02
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5.3.2.4 The tetrahydrocarbazole scaffold
Those fragment hits containing isatin, phenylpiperazine, imidazole or indazole rings,
which led us to the carbazole scaffold, also led to the identification of the
tetrahydrocarbazole scaffold (Figure 5.10) that differs only in the saturation of one of
the rings. Commercially available compounds with the tetrahydrocarbazole scaffold,
particularly those with halogen substitutions on the rings were obtained and tested.
Many hits were identified, the weaker binders with estimated Ki > 500 µM were not
further explored. The summary data of the hits are in Table 5.8.
5.3.2.4.1 P3E2
P3E2 (6-chloro-2,3,4,9-tetrahydro-1H-carbazole-7-carboxylic acid) was identified
with good affinity (Ki of 216 µM, Figure 5.11, Table 5.8), better than any of the
aforementioned carbazole hits. Its complex crystal structure with the SC (Figure 5.13,
crystallographic data in Table 5.6) was solved, revealing H-bonding between its
carboxylic acid group and the S346 side chain, and a backbone carbonyl oxygen of
V247, which may be critical for its affinity. Moreover, the tetrahydro-ring has a flexible
geometry in comparison with a phenyl ring, thus allowing the tetrahydrocarbazole to
bend and better fit the geometry of the binding site. The S-shaped geometry is caused
by residue P242 which would be an obstruction of a linear and rigid moiety like the
carbazole scaffold. This may also be the reason for the superior binding of P3E2.
It is noteworthy that the gating residue M362 remained closed with P3E2 bound in
subsite I. Given that the carboxylic group of P3E2 is in contact with the side chain of
S346, the carboxylic group could hinder the movement of the M362 Chi2 angle.
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5.3.2.4.2 P5bH1
Compound P5bH1 (6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxylic acid), as
a racemic mixture, was found to inhibit the fluorescent tracer binding to the SC with 64
µM Ki (Figure 5.l2, Table 5.8). Two similar compounds, P4A6 (methyl 6-chloro2,3,4,9-tetrahydro-1H-carbazole-1-carboxylate) and P4H1 (ethyl 6-chloro-2,3,4,9tetrahydro-1H-carbazole-1-carboxylate), as the racemic methyl- and ethyl-esters of
P5bH1, were obtained and tested. They showed much weaker affinity (Figure 5.12,
Table 5.8).
The complex crystal structure of P5bH1 and the SC was solved (Figure 5.14,
crystallographic data in Table 5.7). P5bH1 has a chiral centre and was tested as a
racemic mixture but only the (R)-enantiomer was present in the electron density map
(Figure 5.14). (R)-P5bH1 occupies subsite I but lacks the H-bond found between P3E2
and the S346 side chain (Figure 5.13). Both P3E2 and P5bH1 have a partly saturated
rings with sufficient flexibility to avoid steric clashes with P242. The binding of (R)P5bH1 caused conformation changes in M362 and S346. Its chloro substituent is wellsituated at the hydrophobic deep region. P5bH1 lacks the carboxylate group of P3E2
and hence does not sterically hinder movement of M362 and S346. This may explain
the superior affinity of (R)-P5bH1. The carboxylate group on the cyclohexyl ring can
form a salt-bridge with R152, which may explain the preference for the (R)-enantiomer
in crystallo.
5.4 Conclusion
Two strategies, expansion and merging, were used to grow fragments and led to the
discovery of four scaffolds, the biphenyl scaffold, the phenylpiperazine scaffold, the
carbazole scaffold and the tetrahydrocarbazole scaffold. However, only the biphenyl
scaffold and the tetrahydrocarbazole scaffold fully occupied subsite I. They also have
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superior binding affinity as demonstrated by the inhibition of the fluorescent tracer
binding to the SC compared with the other two scaffolds.
The biphenyl scaffold had few desirable commercially available derivatives and
derivatization was not explored further. Nevertheless, the crystallographic binding pose
of the only hit with the biphenyl scaffold, P1B8, presented a rationale for extending
other hits to the shallow region of the subsite I. The extensive salt-bridge/H-bonds P1B8
has with residues Y154 and R152 appeared to be key for both binding to the shallow
region of subsite I and the relatively high affinity.
The carbazole scaffold had a number of hits with > 500 µM Ki. One of these, P1A7,
led to the design of the tetrahydrocarbazole scaffold with its complex structure with the
SC. The rigid carbazole ring of P1A7 could clash with the adjacent residue P242, as
suggested by its poor electron density. This finding was critical to the design of the
tetrahydrocarbazole scaffold to introduce flexibility to the ligand.
The tetrahydrocarbazole scaffold, as exemplified by P3E2 and P5bH1, is a promising
scaffold whose shape complements the slightly "S" shape of subsite I due the flexibility
of the cyclohexane ring. The cyclohexane ring partially occupies the shallow region,
and substitutions on this ring could potentially result in additionally interaction with
residues Y154 and R152, as demonstrated by P5bH1. Another desirable structural
feature is the formation of H-bonds with S346 that greatly contributing to the binding
affinity of P5bH1. Likely as the result of such features, the Ki values of P3E2 and
P5bH1 are significantly lower than the other tested carbazole and tetrahydrocarbazole
derivatives.
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Figure 5.10 The design of the tetrahydrocarbazole scaffold based on the fragment hits.
The R1, R2 and R3 groups indicate derivatizations on the scaffold observed in purchased
compounds for testing.
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Figure 5.11 Dose-response curve (fitted using variable slope) of P3E2 (6-chloro2,3,4,9-tetrahydro-1H-carbazole-7-carboxylic acid) inhibiting the fluorescent tracer
binding to the SC. Error bars represent ± 1 standard deviation (n=2).
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Figure 5.12 Dose-response curve (fitted using variable slope) of P5bH1 (6-chloro2,3,4,9-tetrahydro-1H-carbazole-1-carboxylic acid) as a racemic mixture inhibiting the
fluorescent tracer binding to the SC. Error bars represent ± 1 standard deviation (n=2).
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Figure 5.13 P3E2 (6-chloro-2,3,4,9-tetrahydro-1H-carbazole-7-carboxylic acid) bound
in the subsite I of Chain A of a crystal of P1 space group. The SC is shown with carbon
atoms coloured white and the carbon atoms of the ligand coloured light green. Noncarbon atoms are in CPK colours. Wire basket represents (2mFo-DFc) electron density
map contoured at 1 σ. Red dashed lines represent H-bonds.
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Table 5.6 Data collection and refinement statistics of E. coli SC in complex with and
P3E2.

Name
Data collection
Space group
Cell dimensions
Resolution (Å)
Rmerge (%)
No. of Reflections
Unique Reflections
Mean I/σ(I)
Completeness (%)
Multiplicity
Refinement
Resolution (Å)
Rwork/Rfree (%)
R.m.s deviations
Bond lengths (Å)
Bond angles (º)
B-factors
M. Chain
S. Chain & Water
Ligands*
Ramachandran Plot Outliers

SCP3E2
P1
a, b, c (Å)/α, β, γ (°)
41.01, 65.13, 73.24/72.95, 85.06, 85.24
40.95-2.30 (2.42-2.30)
14.7(64.3)
112766
29744 (4227)
8.5 (2.2)
92.9 (89.9)
3.8 (3.7)
40.95 -2.30 (2.36-2.30)
26.1(32.1)/33.8(43.3)
0.0042
0.8787
20.9
23.0
51.7
0.56 %

The value for the highest resolution shell is given in parentheses.
*Diffraction data were collected at home-sourced X-ray generator at the wavelength of
1.5418 Å and processed with HKL2000.
*Ligand refers to theP3E2bound with Chain A.
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Figure 5.14 P5bH1 ((R)-6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxylic acid)
bound in the subsite I of Chain A of a crystal of P21 space group. The SC is shown with
carbon atoms coloured white and the carbon atoms of the ligand coloured light green.
Non-carbon atoms are in CPK colours. Wire basket represents (2mFo-DFc) electron
density map contoured at 1 σ. Red dashed lines represent H-bonds.

131

Table 5.7 Data collection and refinement statistics of E. coli SC in complex with and
P5bH1.

Name
Data collection
Space group
Cell dimensions

SCP5bH1
P21
a, b, c (Å)/α, β, γ (°)
79.78, 67.37, 81.12 /

Resolution (Å)
Rmerge (%)
No. of Reflections
Unique Reflections
Mean I/σ(I)
Completeness (%)
Multiplicity
Refinement

43.86-1.90 (2.00-1.90)
5.2(39.7)
137425
57937 (7647)
9.8 (2.4)
93.7 (85.6)
2.4 (2.3)

Resolution (Å)
Rwork/Rfree (%)

36.46 - 1.90 (1.95-1.90)
21.4(38.8)/26.1(40.7)

R.m.s deviations
Bond lengths (Å)
Bond angles (º)
B-factors
M. Chain
S. Chain & Water
Ligands*
Ramachandran Plot Outliers

0.0090
1.3791
28.1
33.2
42.1
0.72 %

The value for the highest resolution shell is given in parentheses.
*Diffraction data were collected at home-sourced X-ray generator at the wavelength of
1.5418 Å and processed with HKL2000.
*Ligand refers to the P5bH1 bound with Chain A.
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Table 5.8 Summary data of developed fragments with the tetrahydrocarbazole scaffold.
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Chapter 6
Lead development
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6.1 Introduction
The fragment development efforts described above offer perspectives where multiple
ligand-SC interactions contain conserved features that might be incorporated into newer
generations of molecules. The tetrahydrocarbazole scaffold was chosen for lead
development and a derivative was designed by moving the carboxyl group of P3E2
from the phenyl ring to the cyclohexane ring to resemble a similar substitution in P1B8.
This was in order to mimic the two electrostatic interactions of P1B8 with the side
chains of residues Y154 and R152 (Figure 5.2). Another reason for removing the
carboxyl group from the phenyl ring of P3E2 was that the H-bond formed with S346
could prevent the gating residue M362 from switching to an “open” conformation,
blocking entry of substituted P3E2 derivatives into subsite II.
6.2 Materials and methods
6.2.1 Organic chemistry
Compounds were synthesized by Dr. Louise R. Whittell and undergraduate student
Thomas O'Meley, under the supervision of Dr. Michael J. Kelso from the School of
Chemistry, University of Wollongong. The synthesized compounds were of >95%
purity and confirmed with mass spectrometry (To be published in J. Med. Chem.)
6.2.2 Fluorescence polarization assay
FP assays were conducted as described in Chapter 3.
6.2.3 Crystallization and soaking of compounds
Crystals of the SC were prepared as described in Chapter 2.
6.2.4 Data collection, processing, structural solution and refinement
X-ray diffraction experiments, data processing, structure solution and refinement
were conducted as described in Chapter 2.
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6.3 Results and Discussion
6.3.1 The lead compound (R)-P6B10
The addition of a carboxylic acid group to the tetrahydrocarbazole scaffold (similar
to that found in P1B8) yielded a tighter binding compound, P6B10 (6-chloro-2,3,4,9tetrahydro-1H-carbazole-2-carboxylic acid) with Ki of 166 µM (Figure 6.1, Table 6.2).
The similar binding affinity of P6B10 to the SC compared with P3E2 (which has a Ki of
216 µM) suggests that the relocation of the carboxylic acid moiety was successful, as
the loss of two H-bonds with S346 and V360 was compensated by the formation of new
H-bonds with Y154 and R152. The carboxyl group of P6B10 is located on the
cyclohexane ring of the tetrahydrocarbazole scaffold and thus produced a chiral centre.
The sample of P6B10 prepared and tested as described above was a racemic mixture.
The two enantiomers of P6B10 were therefore separated (by Dr Louise Whittell) in
order to determine the difference in binding affinity. The (S)-enantiomer (LWFB2_63B,
Ki = 246 µM, Figure 6.2 and Table 6.5) showed inferior affinity to the (R)-enantiomer
(LWFB2_62B, Ki = 74 µM, Figure 6.3 and Table 6.5).
The crystal structure of P6B10 in complex with the SC was determined and the
electron density map suggested the presence of the (R)-enantiomer (Figure 6.7,
crystallographic data in Table 6.1). Compound (R)-P6B10 bound to subsite I of the SC
as predicted: the carboxyl group formed an H-bond with the Y154 phenol group and a
salt bridge with the R152 guanidine group. The tetrahydrocarbazole scaffold adopted a
binding pose similar to that of P1B8 (Figure 5.2), resulting in the opening of the gating
residue M362 (Chi2 = -69°, Figure 6.4). The M362 side chain is in the vicinity of both
the phenyl ring of the ligand and the S346 side chain. The S346 side chain appeared to
lie in two conformations, apparently due to both ligand binding and the side chain
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movement of M362. This finding supports the hypothesis that the “open” conformation
of M362 prevents H-bond formation between the ligand and the S346 side chain.
The binding of (R)-P6B10 to the SC mimics the binding of the L4F5 sub-motif of SCbinding LM peptides (See Chapter 3). The chlorine-substituent on the phenyl ring
occupies the same space as the leucine side chain and the cyclohexane ring occupies the
same region as the phenylalanine side chain (Figure 6.5). The carboxylic acid group
forms multiple H-bond interactions with adjacent residues so as to stabilize binding,
which may explain why P6B10 binds more tightly than the AcLF dipeptide which lacks
these interactions at its C-terminal carboxylic acid group (See Chapter 3). The
tetrahydrocarbazole scaffold leans toward gating residue M362 and derivatizations
based on the indole nitrogen may provide opportunities to synthesize derivatives
containing substituents oriented toward subsite II (Figure 6.5).
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Figure 6.1 Dose-response curve (fitted using variable slope) of P6B10 (6-chloro2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid) as racemic mixture inhibiting the
fluorescent tracer binding to the SC. Error bars represent ± 1 standard deviation (n=2).
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Figure 6.2 Dose-response curve (fitted using variable slope) of (S)-P6B10 ((S)-6chloro-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid) inhibiting the fluorescent
tracer binding to the SC. Error bars represent ± 1 standard deviation (n=2).
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Figure 6.3 Dose-response curve (fitted using variable slope) of (R)-P6B10 (P6B10
((R)-6-chloro-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic
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Figure

6.4 (R)-P6B10 ((R)-6-chloro-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic

acid)) bound in subsite I of Chain A of a crystal of P21 space group. The SC is shown
with carbon atoms coloured white and the carbon atoms of the ligand coloured light
green. Non-carbon atoms are in CPK colours. Wire basket represents the 2mFo-DFc
electron density map contoured at 1 σ. Red dashed lines represent H-bonds. Red spheres
represent crystallographic water molecules.
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Table 6.1 Data collection and refinement statistics of E. coli SC in complex with the Renantiomer of P6B10.
Name
Data collection
Space group
Cell dimensions
Resolution (Å)
Rmerge (%)
No. of Reflections
Unique Reflections
Mean I/σ(I)
Completeness (%)
Multiplicity
Refinement
Resolution (Å)
Rwork/Rfree (%)
R.m.s deviations
Bond lengths (Å)
Bond angles (º)
B-factors
M. Chain
S. Chain & Water
Ligands*
Ramachandran Plot Outliers

SCP6B10
P21
a, b, c (Å)/α, β, γ (°)
79.87, 67.26, 81.19/90.00, 114.27, 90.00
50.00-2.05 (2.17-2.08)
4.3(26.1)
169346
49386 (4716)
27.4 (3.5)
96.4 (95.9)
3.43 (3.5)
34.61 -2.05 (2.10-2.05)
21.2(20.5)/27.5(30.7)
0.0057
1.1137
22.6
26.4
34.1
0.43 %

The value for the highest resolution shell is given in parentheses.
Diffraction data were collected at home-sourced X-ray generator at the
wavelength of 1.5418 Å and were processed with HKL2000.
*Ligands refer to the compound bound with Chain A.
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Figure 6.5 Superimposition of SCAcQLALF to SCP6B10. The peptide ligand of SCAcQLALF
(carbon atoms coloured pink) is shown. The SC structure of SCP6B10 is shown with
carbon atoms coloured white and the carbon atoms of the P6B10 coloured light green.
Non-carbon atoms are in CPK colours. Red dashed lines represent H-bonds. Red
spheres represent crystallographic water molecules.

144

6.3.2 Derivatives based on the structure of P6B10
Derivatives of P6B10 were prepared by Dr Louise Whittell to find variants with
tighter binding (Table 6.5). Modifications were made to the carboxyl group and its
position on the cyclohexane ring, resulting in decreased affinity (LWFB1_89B,
LWFB1_93C, LWFB1_91B and LWFB1_94B, Table 6.5). This result emphasized the
importance of the H-bonds and salt bridges of the carboxyl group with the side chains of
Y154 and R152.
The importance of the chloro substituent on the phenyl ring was explored by
replacing it to with fluorine, bromine or iodine (TOMFB1-24, TOMFB1-25 and
TOMFB1-30, Table 6.5). The bromo and iodo substitutions showed slightly increased
affinity while the fluoro substitution had decreased affinity. These effects are likely due
to the different shape complementarities of these halogen substituents with the deep
region of the subsite I (Figure 6.7). bromo substituents on the tetrahydrocarbazole (R)enantiomers were investigated (LWFB2_83B and LWFB2_86B, Table 6.5). These
showed superior affinity to the chloro substituted variants. Thus, compounds containing
both chloro and bromo substitutions were carried forward to the next stage of
development.
6.3.3 Derivatization of the indole NH group of the tetrahydrocarbazole scaffold
The presence of the NH group of the tetrahydrocarbazole scaffold naturally serves as
a synthetic handle. Derivatives at this position were made to find chemical moieties that
mimic the binding orientation of the peptide sub-motifs occupying subsite II (See
Chapter 3). An amide derivative on the indole nitrogen (LWFB2_45E, Table 6.5) was
designed to probe the possibility of using a linker moiety to extend the lead compound
so as to bind in subsite II. The affinity of LWFB2_45E (Ki = 201 µM, Figure 6.6 and
Table 6.5) is similar to that of P6B10 (Ki = 166 µM). The pure enantiomers of
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LWFB2_45E were also made and tested (LWFB2_70C as the R-enantiomer and
LWFB2_79C as the S-enantiomer, Table 6.5). The (R)-enantiomer showed higher
affinity than the (S)-enantiomer, consistent with previous findings.
The crystallographic binding pose of LWFB2_45E was determined (Figure 6.7,
crystallographic data in Table 6.2) and the electron density map suggests the presence
of the (R)-enantiomer. The overall binding pose of (R)-LWFB2_45E is similar to (R)P6B10 and forms H-bonds and a salt bridge with the side chains of Y154 and R152
respectively (Figure 6.7).
As expected, the (R)-P6B10 amide group forms an additional H-bond (2.7 Å, Figure
6.7) with the G174 carbonyl group. This interaction is analogous to the H-bond formed
between the L4 peptide amide of the LM described earlier (see Chapter 3) that was
suggested to be important for peptide orientation. A comparison of the binding pose of
(R)-LWFB2_45E and the AcLF dipeptide (see Chapter 3) is shown in Figure 6.8.
These two compounds are approximately equal in size and occupy the same region of
the SC binding pocket.
The ability of the amide group of (R)-LWFB2_45E to form an H-bond with G174
led to the formulation of a strategy for lead optimization targeting subsite II. A number
of derivatives with substituents on the amide group were synthesized and tested.
LWFB2_100E, containing a glycine substituent, had a Ki of 12 µM (Figure 6.9, and
Table 6.5), which is similar in potency to most peptidic ligands (see Chapter 3).
LWFB2_100E is an (R)-enantiomer with a bromo substituent (Figure 6.9). The
crystallographic binding pose of LWFB2_100E was obtained (Figure 6.10,
crystallographic data in Table 6.3). LWFB2_100E preserved the H-bond interaction
with the G174 carbonyl group as well as the interactions with the side chains of Y154
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and R152, similar to the binding pose of (R)-LWFB2_45E. It has an additional
carboxylate group with a salt bridge with R152, which likely contributed to its superior
affinity. A similar derivative, LWFB2_81D (Ki = 47 µM, Table 6.5), with a chlorine
substituent was found to be less active than LWFB2_100E. Therefore, only compounds
containing bromo substitutions were produced in further developments.
A comparison of the binding of LWFB2_100E and the binding of AcALDLF is
shown in Figure 6.11. The AcAL sub-motif was missing from the electron density map
due to the inability of the peptide to bind in subsite II (see Chapter 3). The remaining
DLF residues occupy subsite I and the connecting channel to subsite II. The aspartate
residue of this motif forms a salt bridge with the R152 guanidinium group, an
interaction that is mimicked by the carboxylate group of LWFB2_100E. The aspartate
side chain does not appear to contribute much to the peptide binding affinity (see
Chapter 3) whereas the carboxylate group of LWFB2_100E significantly increased the
binding affinity.
In addition to the glycine-containing compound LWFB2_100E, similar compounds
were synthesized containing alternative amino acids. Three compounds (LWFB2_113D,
LWFB3_05C and TOMFB1-51, Table 6.5) were made and tested by Dr Louise Whittell.
LWFB2_113D contained a (D)-phenylalanine residue and showed tight binding with a
Ki of 17 µM (Figure 6.12 and Table 6.5), similar to that of LWFB2_100E. The
crystallographic binding pose of LWFB2_113D was observed (Figure 6.13,
crystallographic data in Table 6.4). In addition to the interactions its predecessors made
with the SC, the side chain of the (D)-phenylalanine moiety of LWFB2_113D is largely
exposed to bulk solvent without significant interactions. LWFB3_05C is a similar
compound made with (L)-phenylalanine with a Ki of 18 µM. The crystal structure of
this complex is yet to be obtained due to poor electron density for the ligand. A
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comparison of the binding of LWFB2_113D and the AcQADLF peptide to the SC is
shown in Figure 6.14. The side chain of the (D)-phenylalanine moiety of
LWFB2_113D is positioned close to the region that is occupied by the alanine residue
of the AcQADLF peptide.
Peptide binding at subsite II features an H-bond network between the glutamine
residue and the adjacent subsite residues and a structurally conserved water molecule
(Figure 6.14). The ultimate goal of inhibitor design is to block these interactions.
LWFB2_113D represents a step toward this goal beyond LWFB2_100E, which extends
a moiety from the tetrahydrocarbazole scaffold and is bound to the channel connecting
the two subsites. The side chain of the (D)-phenylalanine of LWFB2_113D may be too
large to fit the channel area, suggesting that other (D)-amino acids (e.g. (D)-Lys, (D)Gln, etc) in synthesis may produce derivatives capable of forming H-bonds in subsite II.
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Figure 6.6 Dose-response curve (fitted using variable slope) of LWFB2_45E (((R)-9(2-amino-2-oxoethyl)-6-chloro-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic

acid)

inhibiting the fluorescent tracer binding to the SC. Error bars represent ±1 standard
deviation (n=2).
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Figure 6.7 (R)-LWFB2_45E ((R)-9-(2-amino-2-oxoethyl)-6-chloro-2,3,4,9-tetrahydro1H-carbazole-2-carboxylic acid) bound in the subsite I of Chain A in a SC crystal of P21
space group. SC is shown with carbon atoms coloured white and the carbon atoms of
the ligand coloured light green. Non-carbon atoms are in CPK colours. Wire basket
represents (2mFo-DFc) electron density map contoured at 1 σ. Red dashed lines
represent H-bonds. The red sphere represents a crystallographic water molecule.
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Table 6.2 Data collection and refinement statistics of E. coli SC in complex with the Renantiomer of LWFB2_45E.
Name
Data collection
Space group
Cell dimensions
Resolution (Å)
Rmerge (%)
No. of Reflections
Unique Reflections
Mean I/σ(I)
Completeness (%)
Multiplicity
Refinement
Resolution (Å)
Rwork/Rfree (%)
R.m.s deviations
Bond lengths (Å)
Bond angles (º)
B-factors
M. Chain
S. Chain & Water
Ligands*
Ramachandran Plot Outliers

SC45E
P21
a, b, c (Å)/α, β, γ (°)
80.08, 66.20, 80.62/90.00, 114.89, 90.00
40.00-1.90 (1.97-1.90)
2.8(17.1)
219352
60330 (6013)
41.5 (7)
99.9 (100.0)
3.6 (3.5)
21.62 -1.90 (1.95-1.90)
20.5(23)/25.9(29.1)
0.0195
1.8756
17.1
22.7
33.4
0.69 %

The value for the highest resolution shell is given in parentheses.
Diffraction data were collected at home-sourced X-ray generator at the
wavelength of 1.5418 Å and were processed with HKL2000.
*Ligands refer to the compound bound with Chain A.
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Figure 6.8 Superimposition of SCAcLF to SC45E. SCAcLF is shown with carbon atoms
coloured pink. SCP6B10 is shown with SC carbon atoms coloured white and the carbon
atoms of the P6B10 coloured light green. Non-carbon atoms are in CPK colours. Red
dashed lines represent H-bonds. The red spheres represents a crystallographic water
molecule.
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Figure 6.9 Dose-response curve (fitted using variable slope) of LWFB2_100E ((R)-6bromo-9-(2-(carboxymethylamino)-2-oxoethyl)-2,3,4,9-tetrahydro-1H-carbazole-2carboxylic acid) inhibiting the fluorescent tracer binding to the SC. Error bars represent
± 1 standard deviation (n=2).
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Figure 6.10 SC100E ((R)-6-bromo-9-(2-(carboxymethylamino)-2-oxoethyl)-2,3,4,9tetrahydro-1H-carbazole-2-carboxylic acid) bound in the subsite I of Chain A of a
crystal of P21 space group. SC is shown with carbon atoms coloured white and the
carbon atoms of the ligand coloured light green. Non-carbon atoms are in CPK colours.
Wire basket represents (2mFo-DFc) electron density map contoured at 1 σ. Red dashed
lines represent H-bonds. Red spheres represent crystallographic water molecules.
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Table 6.3 Data collection and refinement statistics of E. coli SC in complex with the Renantiomer of LWFB2_100E.
Name
Data collection
Space group
Cell dimensions
Resolution (Å)
Rmerge (%)
No. of Reflections
Unique Reflections
Mean I/σ(I)
Completeness (%)
Multiplicity
Refinement
Resolution (Å)
Rwork/Rfree (%)
R.m.s deviations
Bond lengths (Å)
Bond angles (º)
B-factors
M. Chain
S. Chain & Water
Ligands*
Ramachandran Plot Outliers

SC100E
P21
a, b, c (Å)/α, β, γ (°)
80.03, 66.42, 80.79/90.00, 114.76, 90.00
30.00-2.25 (2.33-2.25)
7.1(45.6)
116359
37099 (3029)
16.6 (2.2)
96.4 (82.4)
3.2 (2.6)
29.82 -2.24 (2.29-2.24)
18.9(21.0)/24.9(35.0)
0.0071
1.2525
24.9
26.9
33.8
0.96 %

The value for the highest resolution shell is given in parentheses.
Diffraction data were collected at home-sourced X-ray generator at the
wavelength of 1.5418 Å and were processed with HKL2000.
*Ligands refer to the compound bound with Chain A.
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Figure 6.11 Superimposition of SCAcALDLF to SC100E. SCAcALDLF is shown with carbon
atoms coloured pink. SC100E is shown with SC carbon atoms coloured white and the
carbon atoms of the LWFB2_100E coloured light green. Non-carbon atoms are in CPK
colours. Red dashed lines represent H-bonds. Red spheres represent crystallographic
water molecules.
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Figure 6.12 Dose-response curve (fitted using variable slope) of LWFB2_113D ((R)-6bromo-9-(2-((R)-1-carboxy-2-phenylethylamino)-2-oxoethyl)-2,3,4,9-tetrahydro-1Hcarbazole-2-carboxylic acid) inhibiting the fluorescent tracer binding to the SC. Error
bars represent ± 1 standard deviation (n=2).
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Figure

6.13

SC113D

((R)-6-bromo-9-(2-((R)-1-carboxy-2-phenylethylamino)-2-

oxoethyl)-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid) bound in subsite I of
Chain A of a crystal of P21 space group. SC is shown with carbon atoms coloured white
and the carbon atoms of the ligand coloured light green. Non-carbon atoms are in CPK
colours. Wire basket represents (2mFo-DFc) electron density map contoured at 1 σ. Red
dashed lines represent H-bonds. The red sphere represents a crystallographic water
molecule.
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Table 6.4 Data collection and refinement statistics of E. coli SC in complex with the Renantiomer of LWFB2_113D.
Name
Data collection
Space group
Cell dimensions
Resolution (Å)
Rmerge (%)
No. of Reflections
Unique Reflections
Mean I/σ(I)
Completeness (%)
Multiplicity
Refinement
Resolution (Å)
Rwork/Rfree (%)
R.m.s deviations
Bond lengths (Å)
Bond angles (º)
B-factors
M. Chain
S. Chain & Water
Ligands*
Ramachandran Plot Outliers

SC113D
P21
a, b, c (Å)/α, β, γ (°)
79.86, 67.22, 81.07/90.00, 114.23, 90.00
30.00-2.05 (2.12-2.05)
4.2(38.2)
175983
50262 (4497)
27.9 (2.6)
95.0 (90.1)
3.6 (3.2)
26.64 -2.03 (2.08-2.03)
23.1(27.9)/27.6(41.3)
0.011
1.5432
22.9
26.5
41.5
0.96 %

The value for the highest resolution shell is given in parentheses.
Diffraction data were collected at home-sourced X-ray generator at the
wavelength of 1.5418 Å and were processed with HKL2000.
*Ligands refer to the compound bound with Chain A.
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Figure 6.14 Superimposition of SCAcALDLF to SC100E. SCAcALDLF is shown with carbon
atoms coloured pink. SC100E is shown with SC carbon atoms coloured white and the
carbon atoms of the LWFB2_100E coloured light green. Non-carbon atoms are in CPK
colours. Red dashed lines represent H-bonds. Red spheres represent crystallographic
water molecules.
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6.4 Conclusion
Based on the developed fragments described in Chapter 5, a lead molecule, P6B10
that possesses an indole NH group as a synthetic handle was designed, enabling the
design of inhibitors targeting subsite II. Our previous studies regarding linear motif
recognition suggest that this strategy may improve ligand affinity.
Compound P6B10 mimics the binding of the L4F5 sub-motif. The chlorine atom on
the phenyl ring occupies the same volume as the peptide leucine side chain, and the
cyclohexane ring occupies the space occupied by the phenylalanine side chain. The
carboxylic group engaged in multiple H-bonds and stabilized the binding. The
tetrahydrocarbazole scaffold leans toward the gating residue M362 and the indole
nitrogen provides a vector pointing toward the passage to the subsite II.
The crystal structure of P6B10 in complex with the SC suggested the preference for
the (R)-enantiomer and thus the differences in the binding affinity of the (R)- and (S)enantiomers were explored. Additionally, the effects of different halogen substituents
on the tetrahydrocarbazole scaffold were explored. The results indicate that the (R)enantiomer with a bromo substituent is optimal and this scaffolds containing this
halogen were used to make derivatives at the indole NH group.
In the complex crystal structure of (R)-P6B10 with the SC, the gating residue M362
is in its “open” conformation. Tetrahydrocarbazole derivative LWFB2_45E was
designed, synthesized and tested with a goal of blocking the passage between subsites.
This compound was able to form an H-bond with the G174 carbonyl group, similar to
the H-bond formed by SC-binding peptides. LWFB2_45E is approximately equal in
size to the SC-binding dipeptide AcLF, reproducing the overall binding pose of AcLF in
subsite I as well as the H-bond with G174, and demonstrated tighter binding.
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LWFB2_100E was developed from LWFB2_45E by addition of a glycine residue.
The carboxylate of this glycine moiety makes a salt bridge with the R152 side chain and
may explain its high affinity (Ki = 12 µM). This carboxylate group binds in the channel
connecting the two subsites that could be occupied by the aspartate residue of the SCbinding pentapeptides. Thus the design mimicked the peptide binding strategy by
reproducing the binding orientation and key interactions.
LWFB2_113D was designed based on LWFB2_100E to further explore amino acid
substitutions of the tetrahydrocarbazole. LWFB2_113D contains a (D)-phenylalanine
residue that replaces the glycine residue in LWFB2_100E. The side chain of the (D)phenylalanine residue reached the edge of subsite II, indicating further strategies for
optimizing the lead molecule based on the structure of LWFB2_100E.
Both LWFB2_100E and LWFB2_113D have ~10 µM affinity, similar to the peptidic
binders but are smaller in size, and thus possess higher ligand efficiency. They also
possess ideal lipophilic ligand efficiency (Table 6.5) and thus suitable for further
modifications that may increase the affinity while maintaining the drug-like profile.
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Table 6.5 Summary data of developed fragments with the tetrahydrocarbazole scaffold.
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Chapter 7
Discussion
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There is an indisputable need for new classes of antibiotics acting through new
targets. Therefore, the identification of new compounds acting against novel bacterial
targets is of great interest. The aim of the work described in this thesis was to develop
small-molecule inhibitors of the E. coli SC as a critical component of the bacterial DNA
replication and repair machinery. Such inhibitors may serve as a novel class of
antibiotics with a novel mechanism of action. Since bacterial SCs appear to have
conserved structures,30,31,37 potent SC inhibitors could demonstrate broad-spectrum
activity. The SC functions by recognizing various LMs in binding partner proteins and
thus the binding mechanism was studied. Understanding of the LM binding mechanism,
together with structural data from fragment screening guided the design of inhibitors.
Several inhibitors mimicked the binding mode of the LMs with superior affinity.
7.1 The mechanism of LM recognition by the E. coli SC shed lights on ligand
design
LMs are frequently observed to mediate critical protein-protein interactions during
signalling, cell proliferation and other regulatory processes. An on-line database called
ELM (http://elm.eu.org/) contains biochemical and sequence data for a large number of
eukaryotic linear motifs (of 4-20 residues) and their interacting partners. Despite being
widely observed in nature, the binding processes of LMs by their receptors are poorly
understood due in part due to LMs being disordered prior to binding.111
LM recognition by the E. coli SC of the bacterial DNA replication machinery was
examined. The E. coli SC mediates replisome formation and other interactions via
recognition of LMs in various binding partners. Using the techniques of
biochemistry/biophysics, molecular dynamics simulations and X-ray crystallography, a
structural

and

thermodynamic

dissection

of

the

optimally-binding

peptide

Ac0Q1L2D3L4F5 binding to the E. coli SC was performed. Interactions made by -Q1- and
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-L4F5 were found to be important structural determinants of LM recognition by the SC.
Molecular dynamics simulations supported the hypothesis that the binding free-energy
is diminished by the loss of conformation entropy as a result of peptide binding and
deformation. Similar conformational entropy loss upon ligand binding was observed in
the computational study of an HIV-derived PTAP-containing nonapeptide binding to
the Tsg101 ubiquitin E2 variant domain.111 Fong and co-workers performed a largescale computational study of intrinsically disordered regions in proteins-protein
complexes using hundreds of different protein complexes, suggesting that disordered
peptides becoming structured upon binding is a fairly common phenomenon.95 The
energetic profile of pentapeptides binding to the E. coli SC therefore appears to be
typical of LM-binding and the observations reported here may assist in the
understanding of interactions involving LMs generally.
An anchor-based model of sequential binding of peptides to the SC was proposed:
the -L4F5 sub-motif acts as the anchor, establishing the initial contact with SC subsite I,
followed by the formation of a hydrogen-bonding network between the flanking
residues and subsite II to stabilize the interaction. This model is supported by steered
molecular dynamics simulations and crystal structures of the SC in complex with the
dipeptide AcLF. A gating residue, M362, separates subsite I from subsite II and
displayed alternate open and closed conformations depending on ligand binding. In the
structure of the SC/AcLF complex, the open conformation of the M362 gating residue
was observed. This dipeptide was proposed to represent the minimal binding element.
Biochemical measurements established that the -Q1L2- sub-motif could not bind in the
absence of -L4F5. SMD calculations suggested that the -Q1L2- sub-motif only binds after
binding of the -L4F5 sub-motif. To account for this apparent sequential binding, the
almost-buried polar atoms (ABPAs) of subsite II were proposed to create a kinetic
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barrier to the binding of the peptide -Q1- residue. Steered molecular dynamics
simulations were used to create a profile of the kinetic barrier.
The anchor-based model of sequential binding offers an insight into the LM
recognition by the E. coli SC and potentially LM-binding in general. A similar model
was proposed to account for a very similar case: Lacy and co-workers found that a
conserved RxLFG motif of p27 establishes the first contact with cyclin A followed by
folding of the disordered region containing this hydrophobic motif, likely due to the
lower barrier of dehydration as compared to the rest of the sequence.106 These
observations suggest that sequential binding is guided by hydrophobic motifs, and that
this may be a common feature in LM recognition.
7.2 Fragment-based screening of binding inhibitors of the E. coli SC by X-ray
crystallography
A fragment-based screen of the SC by X-ray crystallography was undertaken to find
fragment-like compounds binding to the LM-binding pocket. A total of 352 fragment
compounds were screened by X-ray crystallography and in addition to several pseudohits and partial hits, four fragment compounds (ZT0602, ZT0250, ZT0447 and ZT0445)
were identified as valid hits with distinguishable electron density in 2mFo-DFc maps
that unambiguously revealed their binding poses.
All fragment hits were found to occupy subsite I of the binding pocket. This is
consistent with the sequential binding model of LM recognition by the SC, where the
subsite I serves as the “anchor site”, and must be occupied prior to subsite II. All hits
had aromatic ring(s) bound at the deep region of subsite I that accommodates the
leucine side chain of the LF sub-motif frequently found in the SC-binding LMs.
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The fragment hits were estimated to bind to the SC with dissociation constants in the
millimolar range. The binding affinity cannot be accurately measured since the
compound solubility capped the measurable range of inhibitor concentrations. Ligand
occupancy of the fragments were used to estimate the approximate Kd based on the
temperature factors of a ligand atom relative to the closest receptor atom (the SC) (See
Chapter 3). In turn, the occupancy was used to estimate the approximate Kd as the
affinity in crystallo. The calculated Kd values also suggested millimolar Kd affinity for
all fragment hits and further analysis of their lipo-ligand efficiency provided aid in
decision of which fragment to be entered into the next round of development.
7.3 Fragment growth and lead development aided with X-ray crystallography
Three strategies, expansion, merging and tethering, were used to grow fragments.
Molecular docking was used as a tool to explore the plausible binding poses of inhibitor
candidates retrieved from the online compound library UCSF ZINC136 by similarity and
substructure searches based on the fragment hits. Although docking failed to identify a
binder with superior affinities, it nevertheless led to the discovery of four scaffolds: the
biphenyl scaffold, the phenylpiperazine scaffold, the carbazole scaffold and the
tetrahydrocarbazole scaffold. Binding of compounds from these four classes to the SC
was observed by X-ray crystallography. Only the biphenyl scaffold and the
tetrahydrocarbazole scaffold occupied all of subsite I. The biphenyl and
tetrahydrocarbazole derivatives had superior binding affinity for subsite I, as
demonstrated by the inhibition of the fluorescent tracer binding to the SC compared
with the other two scaffolds. The phenylpiperazine derivatives are half-buried in subsite
I and half-exposed in bulk solvent. Only the carbazole derivatives occupied the deep
region of subsite I.
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The biphenyl scaffold had few desirable commercially available derivatives and
these were not explored further. Nevertheless, the crystallographic binding pose of the
only hit with the biphenyl scaffold, P1B8, presented a rationale for extending other hits
to the shallow region of the subsite I (Figure 5.1 and 5.2). The extensive salt-bridge/Hbonds P1B8 forms with adjacent residues are the key for both binding in the shallow
region and the affinity.
The tetrahydrocarbazole scaffold, exemplified by compounds P3E2 and P5bH1, was
considered to be a more promising structure whose shape complements the slight “S”
shaped curve of subsite I due the flexibility of the cyclohexane ring. The cyclohexane
ring was observed to partially occupy the shallow region, and substitutions on this ring
were postulated to result in additional H-bond interactions with residues Y154 and
R152. These interactions were demonstrated by the binding of P5bH1, containing a
carboxylic acid on the cyclohexane ring, to the SC. (The addition of this functional
group resulted in the creation of a new chiral centre.) A structural feature contributing to
affinity of P3E2 is the formation of H-bonds between the carboxylic acid group and the
side chain of S346, greatly contributing to its binding affinity. Likely as the result of
these features, the Ki values for P3E2 and P5bH1 are significantly lower than the other
carbazole and tetrahydrocarbazole derivatives tested.
Tetrahydrocarbazole derivative P6B10 was designed based on the structures and
binding poses of P1B8, P3E2 and P5bH1. The crystal structure of P6B10 in complex
with the SC suggested the (R)-enantiomer was preferred and thus the differences in the
binding affinity of the (R)- and (S)-enantiomers were explored. The effects of different
halogen substituents on the tetrahydrocarbazole scaffold were also explored. The results
suggested superior affinity of the (R)-enantiomer with a bromine substituent. The
resulting molecule, P6B10, was then used as a lead scaffold for derivatization of the
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indole NH group. It was postulated that derivatives of the indole-functionalized branch
could occupy the channel connecting the two subsites.
A tetrahydrocarbazole derivative, LWFB2_45E, was designed containing an amide
derivative at the indole nitrogen. It was observed to form an H-bond with the G174
carbonyl group, similar to the H-bond formed between the backbone amide group of
residue -D3- of the consensus peptide and residue G174. LWFB2_45E is approximately
equal in size to SC-binding dipeptide AcLF, reproducing the overall binding pose of
AcLF in subsite I as well as the H-bond with G174, but with tighter binding. A further
modification, addition of a glycine to the amide was made (LWFB2_100E) and the Cterminal carboxylate of this glycine moiety was observed to form a salt bridge with the
R152 side chain and may explain its high affinity (Kd ~ 12 µM). This carboxylate group
binds to the channel connecting the two subsites that would be occupied by consensus
peptide residue -D3-. Thus the design further mimicked the peptide binding strategy by
reproducing the binding orientation and key interactions.
LWFB2_113D was designed based on LWFB2_100E to add additional features of
the consensus peptide. LWFB2_113D contains a (D)-phenylalanine residue replacing
the glycine residue in LWFB2_100E. The side chain of the (D)-phenylalanine residue
reached the edge of subsite II, lying adjacent to the side chain of M362. Future
optimization includes a screening of (D)-enantiomers of amino acids that can be
incorporated into the lead molecule based on the structure of LWFB2_100E, and thus
could result in a compound that binds to both subsites I and II.
7.4 Future directions
The optimal binding inhibitors LWFB2_100E and LWFB2_113D have Kd ~10 µM
affinity with potential for further increases in affinity. Future developments will focus
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on growing the best compounds so as to target subsite II by reproducing the critical Hbond network of peptide ligands. The two small-molecule inhibitors possess ideal
lipophilic ligand efficiency and are thus suitable for further modification with the aim of
increasing affinity while maintaining a drug-like profile.
Future work could include lead optimization as well as structural characterization to
guide design. Functional assays (e.g. as described by Jergic and co-workers)140 will be
valuable in correlating the inhibition of peptide binding by the FP assay to inhibition of
in vitro DNA replication. Anti-bacterial testing will be used to measure the efficiency of
those SC inhibitors as novel antibiotics. Once in vitro and/or in vivo efficacy was
established for the developed compounds, further medicinal optimization may be
carried out to improve ligand affinity and thus drug efficiency.
The current work used the E. coli SC as the model target because it is easy to express,
purify and crystallize, and it is structurally conserved across species. However, small
differences may exist in the constitution of the SC binding pocket in different species.
Investigation of inhibitors against a variety of bacterial strains and their isolated SC
proteins may further our knowledge of the potential of SC inhibitors as broad-spectrum
antibiotics.
Successes in fragment-based drug design targeting protein-protein interactions are
relatively few compared with enzymes. An example of success in this area was
fragment-based screening of heat shock protein 90 (Hsp90) using NMR, ITC and X-ray
crystallography.141,142 Hsp90 is a molecular chaperone for modulating protein stability
and a key component in the heat shock response.143,144 Over-expression of Hsp90 is
related to carcinogenesis and can be found in various cancer types.145-147 The inhibition
of Hsp90 has been a popular area of research interests during the last decade and
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progress had been made in diversifying inhibitor chemotypes.148 An aminopyrimidine
fragment was found and the crystal structure of its complex with Hsp90 guided
optimization toward leads with nanomolar potency and sound ligand efficiency. The
development started with the fragment hit's complex crystal structure with Hsp90 by
filling the proximal lipophilic pocket which was achieved by substitution on the upper
phenyl ring with small groups. Ligand efficiency was monitored along the way to the
finding of a potent lead, which adopts the same orientation of the starting fragment
while the interactions are maintained. The work presented here used similar methods
(i.e. X-ray crystallography) to identify the fragment hits, and a similar strategy in
expanding the fragments to larger lead-like molecules, including monitoring and
retaining LLE. Our design effort differed with respect to Hsp90 inhibitor development
in the way that the E. coli SC binding pocket is separated into two subsites. This
complicated the inhibitor development effort and demanded an in-depth investigation of
the binding mechanism of peptides, which in turn guided the design of small-molecule
inhibitors.
Another example of the use of fragment screening in the development of PPI
inhibitors was the development of compounds to block the interaction of interleukin-2
(IL-2) with its receptor (IL-2R). This interaction stimulates T-cell proliferation, and is
thus involved in the T-helper 1 (Th1) immune response.149,150 Arkin et al. discovered a
small-molecule inhibitor of IL-2 and the structure of its complex with IL-2 served as the
basis of fragment-based design.68 This compound underwent modification by
substructure replacement and new lead series was subject to fragment tethering.151 In
the tethering approach, a library of fragments containing sulfhydryl groups are screened
against a protein target containing cysteine residues (usually introduced by

point

mutantion). Under appropriate redox conditions, fragments with optimal interactions
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with the target binding site will undergo disulfide exchange, forming mixed disulfides
with the target, and may be detected by mass spectrometry. Hits against IL-2 were
merged to the lead structure and resulted in 5-50-fold improvements in potency over the
starting scaffold. The underlying principles of this strategy and efforts to extend the
tetrahydrocarbazole scaffold to subsite II by derivatization on the indole NH group are
similar: a single fragment is not enough for measurable binding to an obstructed or
hidden pocket, which can be energetically unfavourable. Therefore, fusing them to
either the residues near the expected binding pocket or an existing binder may overcome
the energy barrier and produce net increased affinity.
A tethering strategy could be used to improve our SC inhibitors. Specifically, a
tetrahydrocarbazole scaffold similar to LWFB2_113D but with (D)-cysteine in place of
(D)-phenylalanine (see Chapter 5), may serve as parent compound that is subject to
disulfide exchange with sulfhydryl-containing fragments in order to find those that
occupy subsite II as suggested by the binding pose of LWFB2_113D.
In summary, the work presented here adds to the growing number of successful cases
of inhibitor development against protein-protein interactions. Similar to the fragmentbased development of Hsp90 and IL-2 inhibitors, the affinity of the SC inhibitors was
improved from millimolar to low-micromolar range. Expansion was used as the design
strategy, but the idea of merging and tethering also inspired the design of P6B10 and the
effort to target subsite II. A thermodynamic elucidation of the nature of LM/SC
interaction was undertaken and the insights gained from this study guided the design of
small-molecule inhibitors. Such strategies of mimicking the physiological proteinprotein/protein-ligand interaction with synthetic compounds should be applicable to
medicinal design in general.
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Appendix Table 1. The First-Pass Screen library from Zenobia Therapeutics chosen as the fragment library for screening (Plate 1).
P1 1
2
3
4
5
6
7
8
9
10
11
10
26
25
28
27
32
4
23
73
17
75
A

12
37

6

13

24

68

69

99

74

29

102

78

79

80

7

19

71

90

97

218

100

101

270

103

106

109

8

20

72

96

204

274

259

269

279

271

281

296

12

91

89

119

220

287

275

278

292

280

282

320

22

143

93

219

249

391

289

290

399

400

335

402

77

191

209

250

393

394

395

398

424

427

401

429

411

412

413

414

417

418

419

422

426

602

428

446

B

C

D

E

F

G

H
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Appendix Table 2. The First-Pass Screen library from Zenobia Therapeutics chosen as the fragment library for screening (Plate 2).
P2 1
2
3
4
5
6
7
8
9
10
11
12
38
31
44
56
48
42
50
40
30
45
49
39
A
110

84

87

41

196

201

82

83

184

244

131

214

9

125

126

200

862

206

217

252

256

246

261

326

215

328

199

329

408

387

313

389

396

260

421

336

327

405

406

407

445

409

410

425

430

415

431

403

404

449

450

451

452

464

465

468

470

591

864

447

448

535

543

545

547

550

604

581

583

615

676

529

530

537

557

580

587

588

629

605

614

702

717

B

C

D

247

E

F

G

H
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Appendix Table 3. The First-Pass Screen library from Zenobia Therapeutics chosen as the fragment library for screening (Plate 3).
P3 1
2
3
4
5
6
7
8
9
10
11
57
212
358
356
370
273
357
54
173
272
267
A
262

265

266

312

268

305

316

441

442

303

308

435

437

438

439

440

462

463

432

434

584

585

622

623

635

625

626

589

600

601

633

634

693

642

696

563

609

621

630

691

692

749

695

687

688

689

690

757

758

759

782

784

726

791

804

805

807

B

12
371

443

652

582

627

628

669

680

699

686

725

701

716

748

740

763

764

760

761

762

785

786

808

817

818

819

820

C

D

E

546

F

G

H
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Appendix Table 4. The First-Pass Screen library from Zenobia Therapeutics chosen as the fragment library for screening (Plate 4).
P4 1
372
A

2
373

3
478

4
698

5
723

6
724

7
739

8
746

9
N/A

10
N/A

11
N/A

12
N/A

861

647

694

705

733

738

745

747

N/A

N/A

N/A

N/A

703

675

708

709

742

744

765

771

N/A

N/A

N/A

N/A

707

718

731

732

766

769

772

773

N/A

N/A

N/A

N/A

729

730

754

750

796

801

802

803

N/A

N/A

N/A

N/A

787

788

789

790

809

863

813

814

N/A

N/A

N/A

N/A

792

793

794

795

827

860

834

835

N/A

N/A

N/A

N/A

821

823

828

826

848

850

851

852

N/A

N/A

N/A

N/A

B

C

D

E

F

G

H

197

